Stockwinners Market Radar for October 12, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:26 EDT United Insurance estimates $36.4M in Hurricane Ian catastrophe losses - United Insurance "announced that it estimates catastrophe losses incurred from Hurricane Ian during the third quarter ending September 30, 2022, of approximately $36.4 million before income taxes, net of expected reinsurance recoveries. This includes a net retention of $16.4 million split approximately $7.4 million to United Property & Casualty Insurance Company and $9.0 million to American Coastal Insurance Company, plus a $20 million retention by our captive reinsurer, UPC Re."

20:04 EDT Enviva says shortseller report contains numerous errors - Enviva "issued the following statement in response to allegations made in a report by a self-proclaimed short seller. The report contains numerous errors, repeats previous unsupported speculation and gross mischaracterizations, and draws specious, misleading conclusions. The short position on the Company increased substantially in the weeks leading up to the distribution of the spurious report, with almost 4 million shares currently shorted. While the Company acknowledges the role of short selling in creating balance in the public markets, it strongly condemns the unscrupulous practice of "short and distort" campaigns in which short sellers intentionally publish false and misleading claims to needlessly alarm investors and manipulate the market for their own profit."

17:56 EDT Two Harbors estimates book value per common share $4.09-$4.13 - Two Harbors Investment , an Agency + MSR mortgage real estate investment trust announced preliminary estimated financial results for the quarter ended September 30.The company continues to maintain a strong liquidity position while navigating the challenging market environment. Book value per common share was estimated to be between $4.09 and $4.13 per common share as of September 30, after deducting for third quarter 2022 common and preferred dividends declared Comprehensive Loss was estimated to be between 81c and 85c per weighted average basic common share . Earnings Available for Distribution was estimated to be between 15c and 17c per weighted average basic common share. GAAP debt-to-equity was estimated to be 5.5x and economic debt-to-equity was estimated to be 7.5x as of September 30.The company's liquidity position remains strong, with unrestricted cash estimated to be approximately $730M as of September 30.

17:43 EDT Orchid Island Capital announces increase of 4.3M shares to repurchase plan - Orchid Island Capital Board approved an increase in the number of shares of the Company's common stock available in its previously announced stock repurchase program for up to an additional 4.3M shares, bringing the remaining authorization under the Repurchase Program to 5M shares, representing approximately 15% of the Company's currently outstanding shares of common stock.

17:13 EDT Hasbro to produce Dungeons & Dragons documentary, timed with 50th anniversary - Entertainment One, Hasbro's entertainment studio, announced that it will produce the definitive documentary feature about the world's greatest roleplaying game . The Dungeons & Dragons documentary will coincide with the game's 50thanniversary in 2024. Dungeons & Dragons writer and official ambassador Joe Manganiello will co-direct with Kyle Newman and producing alongside his brother Nick Manganiello, Anthony Savini, and Cecily Tyler. Tara Long and Geno McDermott are executive producing for eOne alongside leading Dungeons & Dragons scholar Jon Peterson, Adam F. Goldberg, and Kyle Newman. "I have had the pleasure of working in the past with Joe on True Blood among other projects and cannot think of a better more passionate person to dive headfirst into the world of Dungeons & Dragons from both a player and fan perspective," said Michael Lombardo, eOne's Head of Global Television. "The addition of Kyle Newman, Nick Manganiello, and Jon Peterson also bring unique and multiple dimensions to the history we plan to document. As we approach 50 years of this incredible gaming universe, the time is right for an officially authorized telling of the game's origins and current state of play to its passionate fan based from all walks of life and its global cultural impact

17:05 EDT 908 Devices and CPI partner for cell culture improvement and application - 908 Devices' collaboration with CPI aims to demonstrate the value of at-line cell culture media analysis to inform feeding strategies for improved cell growth in bioprocessing applications. Using data from 908 Devices' REBEL desktop device, CPI process engineers optimized nutrients of a monoclonal antibody-expressing cell line to increase titer and control toxic metabolites. CPI process engineers used the REBEL device to monitor amino acid depletion across a panel of eight commercial cell culture media at high and low glucose concentrations in a 14-day fed-batch process in Ambr 15 micro-bioreactors. Results of the tailored feeding approach, which used a low feed concentration and amino acid supplementation, enabled up to a 40% increase in titer while maintaining low levels of toxic metabolites. The data provided by the REBEL aims to allow users to make informed decisions about their process as well as develop predictive models for feed control, leading to improved efficiency and robust product quality.

17:02 EDT New Gold reports Q3 gold equivalent output 91,021 ounces vs 105,628 last year - Reports Q3 gold production 70,147 ounces vs 72,210 last year. Reports Q3 copper production 8.5 Mlbs vs 15.6 Mlbs last year. "We continued the positive momentum experienced in the summer months and finished the third quarter on a strong note," stated Renaud Adams, President & CEO. "At Rainy River, underground mining commenced during the quarter, and we continue to anticipate underground material to start feeding the mill beginning in the fourth quarter. With mining of the open pit main ODM zone continuing its ramp-up, I look forward to Rainy River finishing the year strong. New Afton had solid production improvement over the second quarter with the continual ramp-up of B3. Last week we received the C-Zone permit, a significant milestone for the mine, and our priority at New Afton continues to be ramping up B3 production and advancing C-Zone development. We remain on track to deliver on our updated guidance."

16:34 EDT Equifax expands integration of lending platform with MeridianLink - Equifax (EFX) is expanding its integration of The Work Number with MeridianLink (MLNK) to now deliver instant verifications of employment and income to credit unions, banks and other lenders through the MeridianLink Consumer Loan Origination System. This builds upon the existing integration serving MeridianLink Mortgage customers. The Work Number is a centralized commercial repository of income and employment data in the U.S., offering credentialed verifiers with permissible purpose access to 573 million records from 2.5 million employers powered by the Equifax Cloud.

16:16 EDT SiriusPoint appoints Steve Yendall CFO effective October 31 - SiriusPoint has announced the appointment of Steve Yendall as Chief Financial Officer, effective October 31.

16:13 EDT Colliers to acquire controlling interest in Arcadia Management, no terms - Colliers announced it will acquire a controlling interest in Arcadia Management Group a commercial real estate property management firm focused in the Southwest U.S. Arcadia's senior leadership will retain a direct equity stake in the business and continue to drive operations going forward under Colliers' unique partnership model. Arcadia will rebrand as Colliers immediately following closing. Details of the transaction were not disclosed.

16:11 EDT USPTO allows Aveo's patent application covering FOTIVDA for refractory cancer - AVEO Oncology announced that, as disclosed on uspto.gov, the United States Patent and Trademark Office has allowed U.S. Patent Application No. 17/720,619, titled "Use of Tivozanib to Treat Subjects with Refractory Cancer". AVEO expects to receive a Notice of Allowance for this Application. This Application will potentially issue as a patent in 2022 and will provide patent protection in the United States for the claimed methods of use of FOTIVDA into 2039. A Notice of Allowance is issued after the USPTO decides that a patent can be granted from a patent application. The majority of patent applications that receive a Notice of Allowance will issue as a U.S. patent once the issue fee is paid. However, a Notice of Allowance is not a guarantee of patent issuance...If issued, AVEO plans to list this patent in the United States Food and Drug Administration's Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations as it relates to FOTIVDA with an expiration date of November 5, 2039.

16:09 EDT Manning & Napier reports AUM of $17.4B as of September 30 - Manning & Napier reported preliminary assets under management as of September 30 of $17.4B, which included approximately $12.4B in separately managed accounts and approximately $5.0B in mutual funds and collective investment trusts. As previously announced, Manning & Napier expects to complete its transaction with Callodine Group in October 2022.

15:56 EDT Grayscale says 'no justification' for SEC denying converion to spot Bitcoin ETF - "Grayscale Investment filed its opening legal brief in the U.S. Court of Appeals for the District of Columbia Circuit challenging the decision by the Securities and Exchange Commission's to deny conversion of Grayscale Bitcoin to a spot Bitcoin ETF. The opening brief explains the legal basis for Grayscale's arguments. On June 29, the SEC denied Grayscale's application to convert GBTC to a spot ETF. The same day, Grayscale Senior Legal Strategist, former U.S. Solicitor General, and partner at Munger, Tolles & Olson, Donald B. Verrilli, Jr., filed a petition for review to initiate the litigation process. Today's brief outlines why the SEC's disparate treatment of these products was arbitrary, discriminatory, and in excess of the Commission's statutory authority; it also argues that the test the SEC has applied to Bitcoin-related ETFs, and only Bitcoin-related ETFs, is flawed and has been inconsistently applied with a "special harshness" to spot Bitcoin ETFs..."That stark arbitrariness cannot be justified or reconciled with the Commission's mandate to treat like cases alike. Rather, it can be only understood as a substantive judgment on the merits of a spot Bitcoin investment - the kind of substantive judgment that is outside the Commission's authority," the brief reads." said the company in a statement. " Reference Link

15:36 EDT EnLink Midstream signs transportation service pact with ExxonMobil - EnLink Midstream (ENLC) announced that it has entered into a transportation service agreement with a subsidiary of ExxonMobil Corporation (XOM). Under the terms of the TSA, EnLink will utilize portions of its existing pipeline network, as well as new facilities, to deliver carbon dioxide from the Mississippi River corridor in southeastern Louisiana to ExxonMobil's 125,000-acre CO2 storage location under development in Vermilion Parish. The TSA includes industry-standard terms and conditions for the provision of transportation services. Ultimate available reserved capacity under the agreement is up to 10 million metric tonnes per year, with initial reserved capacity of 3.2 million metric tonnes per year, beginning early 2025. "EnLink is executing on our first-mover advantage to become the CO2 transportation provider of choice in Louisiana," EnLink Chief Executive Officer Jesse Arenivas said. "Utilizing our extensive network enables us to provide the most timely and cost-effective solution to CO2 transportation, with a significantly lower environmental impact."

15:12 EDT American says oneworld Alliance to relocate global headquarters to Fort Worth - The oneworld Alliance will relocate its global headquarters to Fort Worth, Texas, "joining oneworld founding member American Airlines and strengthening the Dallas-Fort Worth region as a centre of aviation excellence," American announced. Currently located in New York City, the oneworld global headquarters will move to Fort Worth effective December 2022, joining American on its 300-acre, Robert L. Crandall Campus adjacent to Dallas Fort Worth International Airport. "Co-locating with founding member American Airlines, the largest airline in the world, will further accelerate the alliance's drive to deliver greater value for its member airlines and customers. The oneworld central management team will continue to be led by Rob Gurney, who was appointed as CEO in 2016," the company stated. Reference Link

15:02 EDT United Airlines adding new service to three cities, six more flights to Europe - United Airlines announced earlier the debut of the airline's 2023 summer schedule that includes adding new service to three cities - Malaga, Spain; Stockholm, Sweden; and Dubai, UAE - as well as six more flights to "some of the most popular destinations" in Europe, including Rome, Paris, Barcelona, London, Berlin, and Shannon. "In total, United will fly to 37 cities in Europe, Africa, India and the Middle East next summer, more destinations than all other U.S. airlines combined. United saw historic levels of demand for travel to Europe in the summer peak, up 20% compared to 2019, and is focused on developing its network to serve continued demand strength," the company stated. "Next summer United is offering the best of both worlds: we're making it easier for our customers to visit the most popular cities in Europe, but we're also expanding our reach to give travelers access to new places they haven't yet experienced. We expect another busy summer for international travel and are proud to build on our industry-leading global network to offer our customers the widest range of destinations and most convenient travel options," said Patrick Quayle, senior vice president of global network planning and alliances at United.

14:26 EDT Extreme says former employee sold product to sanctioned Russian company - Extreme Networks disclosed that last week it was supplied information by a news organization that helped the company uncover actions taken by a former employee, now working with a Russian distributor, to sell Extreme's product to a U.S. sanctioned company in Russia. The sanctioned company was an indirect customer of a networking business, which Extreme acquired from another company in July 2017. The former employee continued to perpetuate this scheme upon going to work for the distributor after being terminated by Extreme for performance issues, the company said. The total figure of the misappropriated product sales over five years is currently estimated to be approximately $645,000, representing less than 0.01% of the company's global revenue during that time period. Extreme ceased operations in the country in March 2022. The technology that was sold as part of the distributor's scheme was legacy networking hardware used to enable network connectivity. "Extreme takes these matters very seriously. Latham & Watkins LLP, the Company's outside counsel, is assisting with its ongoing internal investigation," it said. Extreme added that it continues to review these matters including whether current and former employees may have been involved. Extreme has notified U.S. regulators.

13:59 EDT Cleveland-Cliffs announces ratification of new labor agreement with USW - Cleveland-Cliffs announced that its new labor agreement with the United Steelworkers, or USW, has been ratified. The contract covers approximately 12,000 USW-represented employees at 13 operating locations, and has a 4-year duration from its starting date of September 1. "Combined with the previously ratified labor agreement covering 2,000 USW-represented employees at the company's mining and pelletizing operations, Cliffs and the USW have concluded the renegotiating cycle with contracts valid through September of 2026," Cleveland-Cliffs said.

13:20 EDT Jeep brand to showcase first-ever BEV Jeep Avenger at 2022 Paris Motor Show - The Jeep brand will showcase a 100 percent electrified presence at the 2022 Paris Motor Show, with a stand fully dedicated to the introduction of the all-new fully electric Jeep Avenger, the brand's first-ever BEV. The all-electric Jeep Avenger will offer Jeep brand capability that is rightsized for the European market delivering a targeted electric range of 400 kilometers, combined with modern and technologically advanced interior, with plenty of space for people and cargo. The new Avenger will be revealed during a press conference hosted by Christian Meunier, the Jeep Brand CEO, at 2 p.m. CET on October 17th. Customers will be able to make reservations for a launch edition of the new BEV immediately after the press conference. The Jeep Avenger will join an already fully electrified European line-up which include 4xe versions of the Jeep Wrangler, Compass, and Renegade. It will also be followed early next year by the launch of the 4xe version of the all-new Jeep Grand Cherokee. In countries such as Germany and France, the Jeep brand offers only electrified SUVs and by the end of the year almost all of the major markets in Continental Europe will offer only electrified SUVs. The Jeep fully electric plan, revealed in September, builds upon this 4xe momentum, calling for the development of a portfolio of capable, fully electric vehicles for Europe. The brand will introduce four zero-emission vehicles in Europe by 2025, with offerings in the main volume segments, including the Jeep Recon and the Wagoneer "S," two all new and all-electric vehicles that will compete in the global mid-size SUV segment. As a result of this product onslaught, all the Jeep vehicles on sale in the region will be 100% electric by 2030.Reference Link

13:02 EDT CJ 4DPlex says 'Top Gun: Maverick' grossed $60M in its premier formats - CJ 4DPlex announced that Paramount Pictures' film "Top Gun: Maverick" has reached new heights with $60M in box office sales in the company's premier theater formats, the visually immersive, 270-degree panoramic ScreenX and the multi-sensory 4DX. This continues to mark the highest grossing title in the company's history, with 4DX surpassing $40M and ScreenX surpassing $20M at the global box office, the company said. With 786 4DX theatres and 370 ScreenX theatres worldwide, CJ 4DPlex's formats combined are now the second largest premium format network in the world. "'Top Gun: Maverick' continues to wow audiences and set more box office records even into October," stated Jongryul Kim, CEO, CJ 4DPlex. "We look forward to continuing our partnership with Paramount Pictures, Tom Cruise, Joe Kosinski and Jerry Bruckheimer and provide global audiences with premium moviegoing experiences that can't be replicated anywhere else."

12:03 EDT JLL Technologies, OpenSpace win bid to support PBS asset and project management - OpenSpace announced it has been selected "as the enterprise-wide image capture solution of choice," alongside JLL Technologies, for the U.S. General Services Administration's Public Buildings Service. "PBS will use OpenSpace Capture to support the management of assets and projects throughout the planning, design, construction, operations, and maintenance life cycle phases. OpenSpace will be partnering with JLL Technologies on the contract and providing program management support for the rollout across all 11 GSA regions... As a part of this selection, OpenSpace is also working towards authorization under the Federal Risk and Authorization Management Program, or FedRAMP, a government-wide security authorization program for cloud-based services. With the onset of the COVID-19 pandemic, PBS began to explore ways to use technology to manage projects remotely. Following a successful pilot, PBS sought an enterprise-wide solution and selected JLL/T and OpenSpace as the provider of choice through GSA's Multiple Award Schedule," the companies stated.

12:00 EDT Enviva falls -17.5% - Enviva is down -17.5%, or -$10.32 to $48.65.

12:00 EDT Universal Insurance rises 8.1% - Universal Insurance is up 8.1%, or 69c to $9.26.

12:00 EDT Gatos Silver rises 22.5% - Gatos Silver is up 22.5%, or 58c to $3.16.

11:47 EDT PHX Minerals completes divestiture, additional mineral acquisitions - PHX Minerals announced that it has closed on the previously announced sale of all its remaining legacy non-operated working interest wellbores in the Fayetteville Shale play in Arkansas to an undisclosed buyer for a total of $6.05M. This divestiture represents 210 gross legacy wellbores and removes approximately $212,000 in asset retirement obligation from the company's balance sheet. On a pro forma basis, PHX has 789 gross legacy non-operated working interest wellbores remaining. Additionally, PHX completed the acquisition of approximately 575 net royalty acres located primarily in Caddo and DeSoto Parishes, Louisiana, for $6.23M. These acquisitions are predominately located in the same focus area of the Haynesville Shale as the company's previously closed royalty acreage acquisitions where drilling activity continues to accelerate. Chad Stephens, President and CEO, said, "These transactions are a continuation of our strategy to high grade PHX's asset base by divesting legacy non-operated working interest wellbores and reinvesting the proceeds in higher margin royalty minerals in our core areas of focus. Also, we anticipate the core focus areas in which we are acquiring minerals to be the leading basins in U.S. natural gas production growth over the next several years. Reputable, well-capitalized operators are actively developing these areas. As such, we expect royalty volumes to continue to increase from the development of acquired minerals in future quarters, which will drive higher future cash flows."

11:29 EDT Century Aluminum trading resumes

11:19 EDT Century Aluminum trading halted, volatility trading pause

11:06 EDT Compass Pathways announces Phase 3 program design for COMP360 - COMPASS Pathways announced the Phase 3 pivotal program design for COMP360 psilocybin therapy in treatment resistant depression during a virtual Capital Markets Day. COMPASS' program will be the first ever Phase 3 program of psilocybin therapy globally, and follows positive results from its Phase 2b study in treatment-resistant depression, presented at the American Psychiatric Association annual meeting in May 2022. The Phase 3 program is composed of three clinical trials, two pivotal trials and one long-term follow-up, and is expected to commence by the end of 2022. The pivotal program design is as follows: Pivotal trial 1: a single dose monotherapy compared with placebo. This trial is designed to replicate the treatment response seen in the company's Phase 2b study. Pivotal trial 2: a fixed repeat dose monotherapy using three dose arms: 25mg, 10mg and 1mg. This trial is designed to investigate if a second dose can increase the number of responders and/or improve response seen in the company's Phase 2b study and explore the potential for a meaningful treatment response from repeat administration of COMP360 10mg. The primary endpoint in both pivotal trials is the change from baseline in MADRS total score at Week 6.

11:04 EDT MGM Resorts announces $100M remodel plan for Mandalay Bay convention center - Mandalay Bay Resort & Casino, which is operated by MGM Resorts International, unveiled details around the $100M remodel of its 2.1 million-square-foot convention center. "With Mandalay Bay home to many of the city's top events and trade shows year after year, we recognized the need to upgrade the space to reflect modern-day needs and create a timeless design complemented by our premier service experience. We listened to feedback from meeting planners over recent years and are confident this refreshed and upgraded space will exceed their needs and expectations in every way," said Ernest Stovall, Vice President of Sales for Mandalay Bay. Mandalay Bay Convention Center will remain open and fully operational throughout the remodel, with upgrades executed in phases, the company said. The project is expected to be complete by the end of 2024.

11:03 EDT Manhattan West named official partner of the New York Knicks - Madison Square Garden Sports announced a multi-year marketing partnership with Manhattan West, naming New York City's newest dynamic destination for food, culture, retail and hospitality an Official Partner of the New York Knicks. Through the partnership, Manhattan West will receive significant brand promotion during Knicks games at The Garden, including LED Signage, on-court contests, concourse tabling and promotional in-game features on GardenVision. Additionally, Manhattan West will be highlighted on the digital boards outside of Madison Square Garden, which are on display to the millions of people who walk by The Garden every day.

10:46 EDT Moderna receives FDA EUA for Omicron-targeting bivalent COVID-19 booster vaccine - Moderna announced that it has received emergency use authorization from the U.S. Food and Drug Administration for its BA.4/BA.5 Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.222, in children and adolescents 6 to 17 years of age. The authorizations are based on a 25 undefined booster dose for children ages 6 to 11 years old and a 50 undefined booster dose for adolescents 12 to 17 years old, each following a completed primary series of any of the authorized COVID-19 vaccines or a previous booster. The booster doses of mRNA-1273.222 each contain mRNA encoding for the spike protein of BA.4/BA.5 as well as mRNA encoding for the original strain of the SARS-CoV-2 virus.

10:19 EDT Pfizer, BioNTech receive FDA EUA for Omicron BA.4/BA.5-adapted bivalent vaccine - Pfizer (PFE) and BioNTech (BNTX) announced that the U.S. Food and Drug Administration granted Emergency Use Authorization for a 10-microgram booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in children 5 through 11 years of age. Pending recommendation from the Centers for Disease Control and Prevention, 10-microgram doses will be shipped immediately. "As families across the country take part in fall festivities and plan for the upcoming holiday season, we aim to provide school-aged children with additional protection against the Omicron BA.4/BA.5 subvariants, which continue to account for more than 80% of cases in the U.S.," said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. "Anticipating this need, we manufactured millions of booster doses, which will be made available, pending CDC recommendation, to help families stay up to date with COVID-19 vaccinations." The authorization of the bivalent COVID-19 vaccine for children 5 through 11 years of age is supported by safety and immunogenicity data from Pfizer and BioNTech's 30-microgram Omicron BA.1-adapted bivalent vaccine, non-clinical and manufacturing data from the companies' 10-microgram Omicron BA.4/BA.5-adapted bivalent vaccine, and pre-clinical data from the 30-microgram Omicron BA.4/BA.5-adapted bivalent vaccine. Clinical data from a Phase 2/3 trial showed a booster dose of Pfizer and BioNTech's 30-microgram Omicron BA.1-adapted bivalent vaccine elicited a superior immune response against the Omicron BA.1 subvariant compared to the companies' original COVID-19 vaccine, with a favorable safety profile. Additionally, pre-clinical data showed a booster dose of the 30-microgram BA.4/BA.5-adapted bivalent vaccine generated a strong neutralizing antibody response against the Omicron BA.1, BA.2, BA.4 and BA.5 subvariants, as well as the original virus. Pfizer and BioNTech have submitted an application to the European Medicines Agency requesting a variation of the companies' marketing authorization in the European Union to include a 10-microgram booster dose of Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in this age group. Similar applications are planned for submission with regulatory authorities around the world in the coming weeks. A Phase 1/2/3 pediatric study is currently underway to evaluate different dosing regimens and dose levels of the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine across age groups.

10:00 EDT Philips falls -11.4% - Philips is down -11.4%, or -$1.71 to $13.21.

10:00 EDT Owens & Minor falls -22.4% - Owens & Minor is down -22.4%, or -$5.19 to $18.03.

10:00 EDT FiscalNote rises 6.8% - FiscalNote is up 6.8%, or 34c to $5.33.

09:56 EDT FDA authorizes new Moderna, Pfizer boosters for younger age groups - The Food and Drug Administration amended the emergency use authorizations of the Moderna (MRNA) COVID-19 Vaccine, Bivalent and the Pfizer (PFE) - BioNTech (BNTX) COVID-19 Vaccine, Bivalent to authorize their use as a single booster dose in younger age groups. The Moderna COVID-19 Vaccine, Bivalent is authorized for administration at least two months following completion of primary or booster vaccination in children down to six years of age. The Pfizer-BioNTech COVID-19 Vaccine, Bivalent is authorized for administration at least two months following completion of primary or booster vaccination in children down to five years of age. Reference Link

09:47 EDT FDA authorizes Moderna, Pfizer omicron booster for younger kids - The Food and Drug Administration amended the emergency use authorizations of the Moderna (NRMA) COVID-19 Vaccine, Bivalent and the Pfizer (PFE) - BioNTech (BNTX) COVID-19 Vaccine, Bivalent to authorize their use as a single booster dose in younger age groups. The Moderna COVID-19 Vaccine, Bivalent is authorized for administration at least two months following completion of primary or booster vaccination in children down to six years of age. The Pfizer-BioNTech COVID-19 Vaccine, Bivalent is authorized for administration at least two months following completion of primary or booster vaccination in children down to five years of age. Reference Link

09:47 EDT Cameco falls -13.2% - Cameco is down -13.2%, or -$3.40 to $22.42.

09:47 EDT UMC rises 4.2% - UMC is up 4.2%, or 23c to $5.58.

09:47 EDT AMTD Digital rises 16.7% - AMTD Digital is up 16.7%, or $6.88 to $48.03.

09:41 EDT AMTD Digital Inc - ADR trading resumes

09:35 EDT AMTD Digital Inc - ADR trading halted, volatility trading pause

09:31 EDT Kinnate Biopharma trading halted, volatility trading pause

09:26 EDT Cemtrex's Vicon announces launch of new LPR camera - Vicon Industries, a subsidiary of Cemtrex, announced the launch of a new License Plate Recognition, LPR, Camera. The Roughneck Pro LPR Camera allows users to capture, store, and search on license plates from over 70 countries, and visually examine details like vehicle color, make, and model in impressive 8MP detail-all from a single camera. "Our LPR camera does the job of two separate cameras: an LPR camera and a 4K surveillance camera," said Bob Germain, Vicon's Director of Camera Products. "Traditionally, LPR cameras require special image configurations and a tighter field-of-view to capture the plate information. This means users could miss additional vehicle details, like make, model, color, vehicle damage, and parking decals, as well as what's going on in the scene around the vehicle," added Bob.

09:22 EDT Black Knight integrates Surefire, Servicing Digital solutions - Black Knight announced a new integration between its Servicing Digital and Surefire marketing automation solutions. This integration allows servicers using Servicing Digital to make valuable content available to homeowners directly within the application. This content works to enhance customer engagement and retention by educating customers on common servicing-related topics throughout their servicing journey. "Communication is a leading factor in customer satisfaction, and Black Knight continues to prioritize the enhancement of self-service tools to give customers the digital capabilities they want," said Joe Nackashi, CEO of Black Knight. "Through this latest integration, servicers can proactively reach out to homeowners with content that's uniquely designed to educate them on common questions and to celebrate milestones. This can contribute to long-term retention by creating meaningful connections between servicers and their customers."

09:20 EDT Pioneer Power awarded $8M purchase order for its flagship E-Bloc solution - Pioneer Power Solutions announced that one of the world's largest automakers has awarded Pioneer an $8M purchase order for its flagship E-Bloc electrical solution. The purchase order was awarded by the automaker's recently launched division that is purely devoted to batteries and EV manufacturing. This order does not include any equipment for the yet to be designed manufacturing hubs, which represents an additional opportunity for the Company. Delivery is scheduled for the third quarter of 2023. "This is an important win for Pioneer, as our solutions were selected in a competitive bidding process across a field that included much larger players," commented Nathan Mazurek, Pioneer's Chairman and Chief Executive Officer. "Our ability to design and deliver special electrical solutions for complex and large applications on a timely and competitive basis was a key differentiator in the selection. This particular automaker is aggressively investing in its electric vehicle infrastructure based on the success of its recently introduced EV cars and trucks and the general, robust demand for EVs. Our solutions will provide resiliency, flexibility and protection for the plant's power needs by seamlessly integrating multiple power sources. We already expected a significant step-up in revenue in 2023, and this win bolsters that expectation and our confidence going forward."

09:17 EDT SLR Investment announces formation of SLR Senior Lending Program - SLR Investment Corp. announces that it has entered into a joint venture agreement with SunStone Senior Credit to create SLR Senior Lending Program. The joint venture is expected to invest primarily in senior secured cash flow loans. SLR Investment Corp. and the Investor each have made initial equity commitments of $50 million, resulting in a total equity commitment of $100 million. SSLP intends to seek third party financing to allow the joint venture to utilize leverage. The Company and the Investor expect to begin funding SSLP with investments prior to the end of 2022. Investment decisions and all other material decisions in respect of SSLP must be approved by representatives of the Company and the Investor.

09:15 EDT Thor Industries increases regular quarterly dividend 5% to 45c per share - Thor Industries approved an increase in the amount of its regular quarterly dividend to 45c per share from 43c per share, an increase of approximately 5%. The regular cash dividend is payable on November 9 to shareholders of record at the close of business on October 26.

09:14 EDT Vicor launches 'Powering Innovation' podcast - Vicor launched the Powering Innovation podcast, which showcases pioneering technologies by the most innovative customers who developed world-changing products through visionary leadership and engineering. The podcasts explore the role power electronics plays in unlocking breakthrough solutions to real-world problems.

09:11 EDT Sage Group announces increased investment in Sage Intacct - Sage announces increased investment in Sage Intacct. Through a series of significant product updates and enhancements, more customers will be able to experience increased productivity and smoother business processes. Delivering against Sage's ambition to become the trusted network for SMBs, the scale of Sage Intacct enables customers to automate processes, boost productivity and free up time to focus on running their businesses.

09:10 EDT BriaCell adds new site to Phase 1/2 trial of advanced breast cancer candidate - BriaCell has added Mayo Clinic, Jacksonville, Florida as a clinical site in the Phase I/II study of BriaCell's lead candidate, Bria-IMT, with Incyte's (INCY) PD-1 inhibitor, retifanlimab, in advanced breast cancer.

09:08 EDT BriaCell adds new site to Phase 1/2 trial of advanced breast cancer candidate - BriaCell has added Mayo Clinic, Jacksonville, Florida as a clinical site in the Phase I/II study of BriaCell's lead candidate, Bria-IMT, with Incyte's (INCY) PD-1 inhibitor, retifanlimab, in advanced breast cancer.

09:07 EDT MGP Ingredients falls 5% to $96.05 following Spruce Point short report

09:06 EDT Hims & Hers names Brian O'Shaughnessy Chief Communications Officer - Hims & Hers Health (HIMS), has added two high-profile executives to its leadership ranks as the company continues to deliver improving financial performance, including rapid topline growth and increasing scale. Silicon Valley communications veteran Brian O'Shaughnessy has been appointed the company's first Chief Communications Officer. Josh Krueger has been named VP of Fulfillment Operations, bringing over a decade of experience in fulfillment leadership roles at Walmart (WMT) and Amazon (AMZN).

09:06 EDT Ibex to showcase CX solution for utilities at Chartwell EMACS conference - ibex announced it will be featuring its latest revenue-generating Beyond the Meter, customer service and customer experience solutions at the Chartwell EMACS Customer Experience Conference, October 17-20, 2022 at the Renaissance Orlando at SeaWorld. ibex will also launch SparkedHome.com, its new utility marketplace solution designed to offer an array of products and services proven to appeal to all utility customer segments and drive the repeat traffic required for long-term success.

09:04 EDT Borqs Technologies demos 2-wheeler telematics control unit - Borqs Technologies announced that the Company has forayed into two/three-wheelers automotive space by developing the Telematics Control Unit and has successfully demonstrated the newly developed TCU in India Mobile Congress held in New Delhi from October 1 to 4. The newly developed TCU is installed on a two-wheeler and connected to the internet via the cellular network.

09:04 EDT Lockheed Martin, Ayar team to advance next generation microchip connectivity - Lockheed Martin and Ayar Labs, a leader in chip-to-chip optical connectivity announced a strategic collaboration to develop future sensory platforms that leverage Ayar Labs' advanced optical I/O microchips that use light to transfer data faster, at a lower latency, and at a fraction of the power of existing electrical I/O solutions. The new platforms could be used across Department of Defense applications to capture, digitize, transport, and process spectral information. "As the complexity and amount of data grows on the battlefield, faster decision-making is essential. New innovative system architectures, coupled with AI and machine learning techniques, are needed for our customers' mission success," said Steve Walker, chief technology officer and vice president, Engineering & Technology at Lockheed Martin. "Ayar Labs' optical interconnect solution provides the necessary technology to process spectral information with greater speed and lower latency for next-generation system designs."

09:02 EDT Codex DNA changing corporate name to Telesis Bio - Codex DNA plans to change its company name to Telesis Bio. There will be no change to corporate structure nor financial reporting.

09:00 EDT Lucid Group produced 2,272 vehicles in Q3 - Lucid Group announced preliminary production and delivery totals for the quarter ended September 30, 2022. The company produced 2,282 vehicles during Q3 at its manufacturing facility in Arizona, more than tripling the number produced in Q2, and delivered 1,398 vehicles during the same period. These figures remain in line with the company's expectations, and Lucid believes it is on track to deliver on its previously provided 6,000 to 7,000 vehicle production guidance for full year 2022.

08:58 EDT Jaguar Health co-sponsors Closing Ceremony at VCS Annual Conference - Jaguar Health is co-sponsoring the Closing Ceremony at the Veterinary Cancer Society Annual Conference to drive awareness of Jaguar's Take C.H.A.R.G.E. initiative. The Closing Ceremony takes place from 6:30 PM - 10:00 PM Eastern Time on Saturday, October 15, 2022 at the conference, which runs October 13-15 in Norfolk, Virginia.

08:55 EDT Park Lawn to acquire Muehlebach Funeral Care in Missouri - Park Lawn announced that it has entered into a definitive agreement to acquire substantially all of the assets of Muehlebach Funeral Care in Kansas City, Missouri, Skradski-Pierce Funeral Home in Kansas City, Kansas and Assurance Cremation Society in Kansas City, Missouri. The Muehlebach acquisition expands Park Lawn's footprint in the Kansas City metropolitan market through the addition of three stand-alone funeral homes. The Muehlebach acquisition is anticipated to close in November 2022 following the receipt of regulatory approval. Highlights of the transactions include: The addition of three stand-alone funeral homes. The transaction represents 627 calls per year and is expected to be financed with funds from PLC's credit facility and available cash on hand. Following the closing and integration of the transaction, the Muehlebach acquisition is expected to add approximately US$616,000 in Adjusted EBITDA annually. For the 12 months ended December 31, 2021, PLC had Adjusted EBITDA of US$76,284,577 and net earnings of US$27,812,866. The agreed upon purchase price multiple for the transaction is within PLC's publicly-stated targeted Adjusted EBITDA multiple range for its historical transactions.

08:51 EDT Sientra signs senior secured loan facilities with Deerfield Management - On October 12, 2022, the Company entered into an agreement with a fund managed by Deerfield Management to refinance the Company's existing term loan and convertible note debt. As a result of the financing, the Company has reduced its total debt load by approximately $10 million, to $73 million, while extending its maturity dates to March 2026 and beyond. Proceeds from the financing are to be used to retire the Company's existing $21 million senior secured term loan facility in full, and related financing expenses. Under the terms of the financing, Sientra entered into a new senior secured convertible note of $23 million, with a conversion price of $1.00, representing a 35% premium over the Company's closing stock price on October 11, 2022. The new note will accrue interest at SOFR + 5.75% per annum and has a 5-year maturity until October 2027. The Company also amended its existing convertible note to make it senior secured debt, reduce the principal outstanding by $10 million to $50 million through a concurrent at-the-market equity exchange with Deerfield, and extend the maturity date by 12 months to March 2026. The conversion price on the existing note was also reset to $2.75, representing an 272% premium over the Company's closing stock price on October 11, 2022. Interest on the existing note remains unchanged at 4% per annum.

08:48 EDT AIM ImmunoTech announces FDA clearance of IND application for Ampligen - AIM ImmunoTech announced its Investigational New Drug application filed with the U.S. Food and Drug Administration may proceed to initiate a Phase 2 study evaluating its investigational drug, Ampligen, as a therapeutic for patients with post-COVID conditions. AIM has pending patent applications for compositions and methods for treating post-COVID conditions with a composition comprising Ampligen. The planned Phase 2 study is a two-arm, randomized, double-blind, placebo-controlled, multicenter study to evaluate efficacy and safety of Ampligen in patients experiencing the post-COVID condition of fatigue. The primary outcome measure of the study is change from baseline to week 13 in PROMIS Fatigue Score. Other study outcomes include: change from baseline to week 6 in PROMIS Fatigue Score; change from baseline to week 6 and 13 in distance traveled during a 6-minute walk test; proportion of subjects with minimal clinically important difference, defined as at least 54 meters, in the Six-Minute Walk Test at the end of 12-week treatment phase; change from baseline to week 6 and 13 in PROMIS Cognitive Function Score; change from baseline to week 6 and 13 in PROMIS Sleep Disturbance Score; and change from baseline to week 6 and 13 in 36-Item Short Form Survey. Approximately 80 subjects between the ages of 18 to 60 years old are expected to be enrolled across up to 10 centers in the United States. Patients will be randomized 1:1 to receive twice weekly IV infusions of Ampligen or placebo for 12 weeks with a follow up phase of 2 weeks. The Company expects to commence patient enrollment and dosing in the AMP-518 study in Q1 2023.

08:45 EDT Tenon Medical to showcase Catamaran SI joint fusion system at NASS - Tenon Medical announced the Company's attendance and planned activities at the37th Annual Meeting of the North American Spine Society. As recently disclosed, Tenon has terminated its legacy distribution agreement with its former distribution partner, SpineSource, and has assumed control of all commercial distribution & sales activities of the Catamaran SI Joint Fusion System. Tenon has begun developing its own commercial infrastructure and sales management team that will partner with key independent spine distributors throughout the country who are motivated to represent the Company's Catamaran. The Company is using the NASS meeting as the national launch event for the Catamaran, which is the only single, titanium fixation device that is implanted from an inferior-posterior approach and transfixes the SI Joint along its longitudinal axis to treat conditions such as SI joint disruption and degenerative sacroiliitis. The Company will have an interactive hands-on technical exhibit where health care providers attending the meeting can learn more about the Catamaran and its novel inferior-posterior approach. Throughout the meeting the Tenon exhibit booth will also host Catamaran "Meet the Expert" sessions where Drs Mark H. Stouffer, MD and Scott C. Kutz, MD will share their Catamaran clinical experience, patient selection criteria and associated clinical outcomes with attendees visiting the exhibit.

08:42 EDT Charlotte's Web, MLB enter exclusive multi-year strategic partnership - Charlotte's Web jointly announced with Major League Baseball, MLB, a first of its kind exclusive multi-year strategic partnership that opens increased CBD visibility to their professional athletes, millions of fans and communities. Major League Baseball now becomes the first major professional sports league to form a sponsorship agreement with a CBD company. "We applaud MLB for being the first-mover in professional sports CBD and are thrilled to welcome their league as a respected strategic partner," said Jacques Tortoroli, CEO Charlotte's Web. "Bridging our industry-leading brands with science, innovation, and education, this pioneering partnership validates Charlotte's Web's core business principle and founding mission to open access to safe, quality and consistent CBD through our proprietary hemp genetics and industry-forging vision."

08:40 EDT T. Rowe Price reports preliminary AUM $1.23T at September 30 - T. Rowe Price Group reported preliminary month-end assets under management of $1.23 trillion as of September 30, 2022. Preliminary net outflows for the third quarter of 2022 were $24.6 billion, bringing preliminary year-to-date net outflows to $44.6 billion. This brings total client transfers for the year-to-date period ended September 30, 2022, to $10.3 billion. These client transfers include $0.2 billion, $2.2 billion, and $7.1 billion, respectively, transferred to the target date retirement trusts during the September, third quarter, and year-to-date periods.

08:38 EDT Asante Gold says Bibiani ramp up, Chirano Mine transition plan on track - BIBIANI RAMP UP ON TRACK: The first gold pour at the Bibiani Gold Mine occurred on July 7, 2022, two months ahead of schedule. All process plant and mine facilities are operating on a 24 hour per day basis, with ~220,000 tonnes of ore treated in September. Asante plans to increase throughput to 250,000 tonnes ore per month by Q1 2023. Gold production in September was just above 9,300 ounces, 17% above the Company's start up plan. Mine plan and mine to mill reconciliation for the Walsh satellite pit and Main Pit were on target. The Walsh Pit continues to outperform, relative to our initial planned gold production. The area between the Walsh and Main pits were historically used for tailings storage. This area has now been partially explored and Measured and Indicated Mineral Resources have increased from 20,000 to more than 100,000 ounces. The drilling program to explore this trend and to support the planned underground mining strategy has been initiated. The Company's plan to extend the Bibiani LOM from 8.3 years to +10 years is on track with successful development exploration at Russel South and drilling programs have commenced at the Grasshopper and Elizabeth deposits. The Company will continue its near mine development exploration program with planned drilling of approximately 30,000 metres per year for 2022, 2023 and 2024. The Company filed an updated National Instrument 43-101 - Standards of Disclosure for Mineral Projects technical report on the Bibiani Gold Mine on September 1, 2022 that incorporates exploration and mine planning results to February 28, 2022 and increased the Measured and Indicated Mineral Resources by 26.4% to 2.29M ounces and are further classified as 1.95M ounces of Proven and Probable Mineral Reserves. An updated NI 43-101 technical report to incorporate results of the 2022 exploration program is planned for Q3 2023. We anticipate this report will define additional ounces to the current resource and LOM. CHIRANO MINE TRANSITION PLAN AND BUSINESS IMPROVEMENTS ON TRACK: The Chirano Gold Mine acquisition was completed on August 10, 2022. This acquisition added Measured and Indicated Mineral Resources of 28.1Mt at 1.26 g/t Au and Inferred Mineral Resources of 6.05Mt at 1.91 g/t to Asante's gold resource. An updated NI 43-101 technical report for Chirano was filed by the Company on October 11, 2022. The technical report is based upon information and planning developed by Kinross Gold Corporation, the former owner of Chirano. Asante continues to identify and develop opportunities to add value to this asset. An update to this technical report is planned for Q3 2023 and will incorporate results of the 2022 exploration program and Business Improvement Plan. The Company has initiated a Chirano Transition and Business Improvement Plan to increase Chirano current gold production by 30% and to reduce AISC by 10% by 2024 through the following initiatives: Gravity plant design and procurement are well advanced with installation planned for completion at Q2 2023; Oxygen addition to the CIL process is proceeding and an oxygen plant is planned for installation in Q2 2023; to date, we have increased gold recovery by +3% to 89%. A pebble crusher has been ordered and primary grinding upgrades are planned to be installed in Q2 2023 to increase process plant throughput from 3.2 to 4.0M t/y; Relocation of minor infrastructure and facilities is underway, to provide access to expansion of the Akoti South open pit and to start the second cut at the Sariehu open pit. These initiatives will access lower cost resources; Studies and associated initiatives are underway to improve the material handling systems to deliver ore to the Process Plant at lower cost; Initiatives to capture synergies between the Bibiani and Chirano mines have started to yield benefits related to supply of principle consumable materials; Development of the wide Obra orebody, the lower Tano underground mines and the Mamnao open pit mine have been accelerated, to provide lower cost resources for treatment; and Asante plans to invest minimum of $5M/y in near mine and regional exploration over the next three years with the target to increase Chirano LOM from current 5 to +10 years; exploration of the Aboduabo and Chine targets has been initiated.OPERATING SYNERGY INITIATIVES UNDERWAY: The Company has commenced initiatives to capture synergies between its' Bibiani and Chirano mines, that are situated with their process plants approximately 15 km apart. These initiatives include development of an access road to directly link the process plants and provide access for exploration along the highly mineralized Bibiani-Chirano shear zone. This road will be upgraded to become a mine haul road, so that ore can be treated where most appropriate, based upon availability and mineralogy. Asante continues to develop opportunities to share infrastructure and to realize operational cost reductions

08:36 EDT Avant Brands, IM Cannabis announce the launch of BLK MKT in Israel - Avant Brands (AVTBF) and IM Cannabis (IMCC) jointly announce the signing of an international trademark licensing agreement granting IMC the exclusive right to launch the BLKMKT brand in the Israeli medical cannabis market. The Licensing Agreement constitutes a significant milestone in the maturing and mutually beneficial relationship between the two premium cannabis companies in the Canadian and Israeli medical cannabis markets. Under the terms of the License Agreement, a subsidiary of Avant will license the Company's premium- cannabis flagship BLKMKT brand to an Israeli subsidiary of IMC for use on IMC's medical cannabis product packaging. All such packaging will contain cannabis cultivated exclusively by Avant, and sold to IMC affiliates. The integration of unique and exclusive varieties of the high-quality BLKMKT brand into the current IMC premium product portfolio will serve to bolster the cooperative and synergistic partnership forged between the two companies over the past two years. It will further strengthen IMC's business model in Israel that offers medical cannabis patients quality, ultra-premium brands, such as WAGNERS, IMC, and more.

08:34 EDT NetSol Technologies launches Flex calculation engine - NETSOL Technologies has launched its latest product offering - Flex, which is an API-based, ready-to-use calculation engine that guarantees precise calculations at all stages of the contract lifecycle through various calculation types. Flex provides versatility by covering all the calculation aspects ranging from the pricing for the end customer at inception, in-life financial modifications, the re-creation of the repayment plan, termination, amortizations/re-amortizations, among other calculation types.

08:34 EDT Capstone Green Energy secures order for two 65 kW systems in Malaysia - Capstone Green Energy announced that Sekito, Capstone's exclusive distributor in Malaysia and Brunei, has secured an order for two 65 kW systems from an independent upstream oil and gas company. The microturbines will be deployed at an unmanned offshore platform on the northwest coast of Malaysia. The microturbines systems are expected to be commissioned in Fall 2023.

08:33 EDT CytoSorbents hosted symposium on CytoSorb, announces presentation data - CytoSorbents also hosted a lunch symposium entitled, "Hemoadsorption with CytoSorb in high-risk cardiac surgery indications - new data" that drew approximately 150 attendees. Key presentations included: "Clinical benefits in patients undergoing heart transplantation - results of a single center RCT." Dr. Endre Nemeth presented the results of the first ever randomized, controlled trial using CytoSorb intraoperatively during cardiac transplantation. Study population: 55 patients were randomized 1:1 to either standard of care or SOC plus CytoSorb. Primary outcome: Need for vasopressors to support blood pressure as measured by the Vasoactive Inotropic Score was significantly reduced by CytoSorb, driven by reductions in both noradrenaline and vasopressin requirements. Importantly, this resulted in significantly lower rates of vasoplegia or vasodilatory shock and shorter overall duration of vasopressor support. Secondary outcomes: All clinical secondary endpoints evaluated in the trial were either similar between the two groups or statistically superior with SOC + CytoSorb including less time on mechanical ventilation, lower rates of postoperative acute kidney injury and fewer days in the ICU. "Removal of antithrombotic drugs to reduce bleeding complications and costs in high urgency operations." Professor Michael Schmoeckel" presented previously published data demonstrating significant bleeding reductions with the intraoperative use of CytoSorb for antithrombotic drug removal in 55 patients undergoing urgent coronary artery bypass grafting and 21 patients undergoing urgent type A aortic dissection repair who were either on ticagrelor or rivaroxaban. Key Outcomes: Among CABG patients, the use of CytoSorb was associated with significant reductions in 24-hour chest tube drainage, platelet and red blood cell transfusions and need for re-operation. Total operative time was also significantly reduced and patients who underwent antithrombotic removal with CytoSorb spent 2 fewer days in the ICU and 5 fewer days overall in the hospital. Similar types and magnitude of benefits were also observed in patients undergoing antithrombotic removal during aortic dissection surgery, but due to the smaller sample size, statistical significance was only achieved for reduction in 24-hour chest tube drainage and platelet transfusions. Publication on "Intraoperative hemoadsorption in patients with native mitral valve infective endocarditis" in 58 consecutive patients showed that CytoSorb led to a significant reduction in the need for vasopressors, a reduced incidence of postoperative sepsis and a significant reduction in sepsis-related mortality in this well-defined population. Publication on "Extracorporeal cytokine adsorption: Significant reduction of catecholamine requirement in patients with AKI and septic shock after cardiac surgery" detailed a case series of 98 high-risk cardiac surgery patients who developed postoperative acute kidney injury and sepsis, and were treated by postoperative continuous renal replacement therapy plus 15 hours of adjunctive hemoadsorption with CytoSorb. Publication on "Intraoperative hemoadsorption in high-risk patients with infective endocarditis" evaluated a series of 70 high-risk patients undergoing cardiac surgery for infective endocarditis. In a propensity-score matched comparison, the SOFA-score normalized significantly faster over a 7-day period in the CytoSorb treated group, among other benefits.

08:28 EDT Pelorus closes $45.5M debt financing with TerrAscend - Pelorus Equity Group announced the closing of its $45.5M debt financing agreement with TerrAscend Corp., and its subsidiaries, TerrAscend NJ, LLC and HMS Hagerstown.. Proceeds from the Loan, which closed Oct. 11, 2022, will support TerrAscend's ongoing growth initiatives.

08:24 EDT Asante Gold files technical report for Chirano Gold Mine - Asante Gold Corporation announced the filing of a technical report in accordance with National Instrument 43-101 - Standards of Disclosure for Mineral Projects in connection with the Company's recently acquired Chirano Gold Mine, located immediately south of the Company's Bibiani Gold Mine. The technical report entitled "NI 43-101 Technical Report, Chirano Gold Mine, Ghana, West Africa" dated September 30, 2022 has been prepared for Asante by dMb Management Services, BARA Consulting Pty Ltd, Snowden Optiro and GB Independent Consulting. The Technical Report includes an updated Mineral Resource Estimate and a Mineral Reserve Estimate along with a detailed mining schedule and economic analysis relevant for continued open pit mining and underground operations. The Technical Report presents a plan which supports the current mining practices and equipment to deliver a robust economic outcome while minimizing execution risk. Asante plans to continue open pit and underground operations at the Mine. Key highlights of the Technical Report include: Measured and Indicated Mineral Resources of 28.1Mt at 1.26 g/t Au and Inferred Mineral Resources of 6.05Mt at 1.91 g/t; Proven and Probable Mineral Reserves of 15.76Mt at 1.95 g/t Au; Life of Mine of five years;Post-Tax NPV of US$258 million at US$1,712/oz Au; AISC of US$1,122/oz Au; Gold recovery of 88.5% yielding 873Koz Au from run of mine grade of 1.9 g/t; Main driver of increase in Indicated Resources is a result of exploration drilling; Significant exploration upside along the developed 11 km of the Chirano Shear Zone and extensive growth potential; Strong community and traditional authority support. The current operating 3.4Mtpa process plant is forecast to treat approximately 16.1Mt of total mineralized material from 2022 to 2026, comprised of both fresh and oxide mineralized material from both open pit and underground sources.

08:20 EDT Rhythm Pharmaceuticals convenes inaugural IMPROVE 2022 - Rhythm Pharmaceuticals announced the inaugural International Meeting on Pathway-Related Obesity: Vision of Excellence 2022 in Berlin, Germany from October 12-14. IMPROVE 2022 is a scientific meeting sponsored by Rhythm for health care professionals based in Europe. Attendees are invited to discuss and share the latest scientific developments and patient care practices related to rare pathway-related obesities, including those driven by impairments in the MC4R pathway, in which genetic deficiencies can result in hyperphagia and early onset severe obesity. At IMPROVE 2022, Rhythm is presenting a poster titled, "Setmelanotide in Patients with Obesity Due to Certain MC4R Variants Stratified as Rescuable or Nonrescuable Based on an In Vitro Functional Assay," which details data from Rhythm's exploratory Phase 2 Basket Study. In this study, Rhythm used an in vitro assay to classify MC4R variants and stratified patients into two cohorts, one of which enrolled patients with predicted setmelanotide rescuable MC4R pathway deficiency and one of which enrolled patients with predicted nonrescuable MC4R deficiency. Twenty-three patients with predicted rescuable MC4R deficiency and 24 patients with predicted nonrescuable MC4R deficiency were enrolled in two cohorts within Rhythm's exploratory Basket Study and all reached three months of treatment with setmelanotide.The in vitro assay demonstrated limited predictive value for setmelanotide response, which was defined as greater than or equal to5% body mass index reduction after three months treatment. Data highlights include: 7 of 23 patients with MC4R variants predicted to be rescuable achieved a greater than or equal to5% BMI reduction at Month 3; Most responders were carriers of the p.S127L heterozygous variant in the rescuable group; 3 of 24 patients with MC4R variants predicted to be nonrescuable achieved greater than or equal to5% BMI reduction at Month 3; Weight loss, as determined by percent change in BMI, tended to increase over time in patients achieving greater than or equal to5% BMI reduction at Month 3, with continued weight loss in responders in both predicted rescuable and nonrescuable groups at Month 6 and Month 9 of treatment with setmelanotide; and The safety profile observed in this study was consistent with that observed with setmelanotide in previous clinical trials in patients with other rare MC4R pathway diseases. No new safety findings were identified.

08:18 EDT Erasca announces four poster presentations at EORTC-NCI-AACR Symposium - Erasca announced four poster presentations at the 34th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics October 26-28 in Barcelona. Preliminary HERKULES-1 Phase 1b data evaluating ERAS-007, an oral ERK1/2 inhibitor, demonstrated encouraging single agent activity and favorable safety and tolerability in patients with metastatic solid tumors refractory to standard therapies. Initial Phase 1b combination data from HERKULES-2 in non-small cell lung cancer are expected in 2023 and from HERKULES-3 in gastrointestinal malignances are expected in the first half of 2023. Preliminary Phase 1 data from the ongoing FLAGSHP-1 trial in advanced solid tumors demonstrated promising single agent safety and tolerability and supported the potential of ERAS-601, a selective SHP2 inhibitor, to enhance efficacy in combination with other targeted therapies. Maximum tolerated doses for BID and QD dosing identified. Treatment-related AEs were reversible, manageable, and consistent with the known mechanism of action for the SHP2 inhibitor class. Initial Phase 1b data from FLAGSHP-1 in combination with cetuximab in patients with triple wildtype CRC are expected in the first half of 2023. ERAS-801 is highly CNS penetrant and has in vitro activity against EGFR alterations observed in NSCLC. Preclinical data support superior anti-tumor activity in these lesions with ERAS-801 relative to osimertinib, the current standard of care treatment for patients with EGFR mutant NSCLC.

08:18 EDT Mirati, Aadi partner to evaluate combination of adagrasib with nab-sirolimus - Mirati Therapeutics (MRTX) and Aadi Bioscience (AADI) announced a clinical collaboration to evaluate the combination of adagrasib, a KRASG12C selective inhibitor, and nab-sirolimus, a small molecule mTOR inhibitor complexed with human albumin in KRAS G12C mutant non-small cell lung cancer, NSCLC, and other solid tumors. The primary objective of this multi-center, single-arm, open-label Phase 1/2 trial is to determine the optimal dose and recommended Phase 2 dose for the combination of adagrasib and nab-sirolimus in patients with KRASG12C - mutant solid tumors. In addition, the study will investigate the safety, tolerability and efficacy of adagrasib and nab-sirolimus in combination in patients both with and without prior exposure to a KRASG12C inhibitor. "We are pleased to collaborate with Aadi on this clinical study of adagrasib and nab-sirolimus. Our collaborative preclinical work has demonstrated that combinatorial mTOR and KRAS inhibition addresses key bypass and feedback pathways associated with either drug target and also results in enhanced efficacy in tumor models harboring KRASG12C mutations. We believe the data from this trial may improve patient outcomes," said Charles Baum, M.D., Ph.D., president, founder and head of research and development, Mirati Therapeutics, Inc. "This clinical collaboration is an example of how Mirati is aggressively advancing the study of adagrasib both as a monotherapy and in rational combinations as part of our expanding development portfolio to benefit people living with difficult-to-treat cancers." Under the terms of the collaboration agreement, Mirati will be responsible for sponsoring and operating the Phase 1/2 study, and jointly with Aadi, will oversee and share the cost of the study.

08:15 EDT Metals Company collects initial batch of seafloor polymetallic nodules - The Metals Company announced that it has successfully collected an initial batch of seafloor polymetallic nodules, and transported them up a 4km-long riser system to the surface, in what represents the first integrated system test conducted in the Clarion Clipperton Zone of the Pacific Ocean since the 1970s. Having successfully completed at-sea construction of the riser system and its integration with the flexible jumper hose and pilot nodule collector vehicle, the dedicated team of 130 crew and engineers aboard the Hidden Gem commenced initial nodule collection runs, driving the pilot collector 147 meters in one hour on a pre-determined path and collecting 14 tonnes of nodules. From inside the collector nodules were channeled to the jumper hose and into the riser where they were lifted on compressed air in a 12-minute-trip from seafloor to the Hidden Gem, where the return water was discharged to the midwater column at depth. To date on the current campaign the collector vehicle has successfully been test-driven approximately 18.1km within NORI-D. Meanwhile, aboard a dedicated 103-meter-long monitoring vessel, expert industry contractors and independent scientists from leading research institutions from around the world are conducting a complex monitoring program to assess the environmental impacts of the collector system trials using an array of over 50 subsea sensors and monitoring stations. The assets are designed to record any changes in the marine environment that may occur during testing of the collector system. The state-of the-art technology that TMC subsidiary NORI has applied to this monitoring effort includes over 20 strategically positioned sediment collection stations; acoustic moorings and landers to measure sound propagation; two Autonomous Underwater Vehicles conducting underwater mapping; two Remotely Operated Vehicles collecting water samples in the plume; optical backscatter and laser diffraction sensors to measure sediment particle settling velocity; trace metal samplers; seven fixed landers equipped with Acoustic Doppler Current Profilers and conductivity, temperature, and depth sensors. NORI expects the findings from the data being collected will be published in scientific literature next year.

08:14 EDT Cognition Therapeutics begins recruitment in Phase 2 trial of Lewy Body Dementia - Cognition Therapeutics is actively recruiting Lewy Body Dementia - or LBD - patients for the SHIMMER Phase 2 trial of their CT1812 oral drug therapy at 17 study sites across the country with more expected to open. Over 1.4 million people in the U.S. are suffering from the neurodegenerative disease, making it the second most common form of dementia. SHIMMER is supported by $30M in grants by the National Institutes of Health's National Institute on Aging. The study is a double-blind Phase 2 clinical trial designed to enroll 120 adults between 50 and 80 years of age with a LBD diagnosis. In addition to safety, this study will compare changes in cognitive performance, physical activity, and pharmacokinetic and pharmacodynamic biomarkers to baseline measurements.

08:12 EDT VEON announces initiatives to bridge IT talent gap in Uzbekistan - VEON announces new initiatives aimed at bridging the IT talent gap in Uzbekistan and supporting the country's plan to become a major IT hub in Central Asia. Working through its Beeline Uzbekistan operating company, VEON will be bringing in leading digital advertising expertise through the opening of a regional hub for AdTech services, and expanding its big data analytics and cybersecurity labs in the country. To accelerate the digital ecosystem of Uzbekistan and Central Asia, VEON will be opening a regional hub of its OTM Global digital advertising organization. The new OTM operation will be hiring up to 70 digital advertising technology professionals over the next year, who will be located on Uzbekistan's new IT Park in Tashkent. The company will initially focus on digital advertising services for the Central Asia markets, with the aim of expanding and becoming a global provider in coming years. VEON will also expand its BeeLab facility in Uzbekistan, creating an advanced expertise in big data analytics and cyber security. By the end of 2023, VEON expects to grow the current BeeLab employee base of 130 to over 250, to establish a core resource of IT professionals in Uzbekistan across the disciplines of data science, software development, Scrum Masters and solution architects. These professionals will expand BeeLab's work on data analytics and cybersecurity for its new and existing financial and fintech clients across Uzbekistan and the Central Asia region.

08:11 EDT Envestnet data, analytics business announce partnership with TCS - Envestnet announced a strategic partnership between Tata Consultancy Services, TCS, and Envestnet Data and Analytics to increase operational scale and business agility. Through this agreement, TCS will help globally scale Envestnet's Data and Analytics business located in Bangalore, India with technologies that anticipate client needs. "We are pleased to partner with TCS to accelerate our response to the growth opportunities in the marketplace, allowing us to gain additional scale and be more dynamic in meeting clients' expectations," said Farouk Ferchichi, Group President, Envestnet Data and Analytics. "TCS will provide our employees with opportunities to grow and expand their careers within an environment that will continue to recognize and value their contributions. As we benefit from the increased scale and agility, we look forward to accelerating our go to market strategy and deepening our customer relationships."

08:10 EDT Spire Global enters launch service agreement with Virgin Orbit - Spire Global (SPIR) has entered a binding launch service agreement with launch provider, Virgin Orbit (VORB) to purchase multiple launches over several years. The first launch is expected to take place in 2023.

08:09 EDT Vor Bio appoints Eyal Attar as Chief Medical Officer - Vor has appointed Bio Eyal Attar as Chief Medical Officer. Attar most recently served as senior vice president and CMO for Aprea Therapeutics. Before Aprea, he held multiple positions in clinical development at Agios Pharmaceuticals, including Senior Medical Director and IDH Hematology Medical Lead.

08:08 EDT Aadi announces preclinical combination data of KRAS inhibitors, nab-sirolimus - Aadi Bioscience announced that preclinical combination data of KRAS inhibitors and nab-sirolimus will be presented during a poster session at the upcoming 34th EORTC-NCI-AACR Symposium, taking place October 26-28, 2022 in Barcelona, Spain. Nab-sirolimus is a novel albumin-bound nanoparticle form of the mTOR inhibitor sirolimus and is approved for the treatment of locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor. KRAS is frequently mutated in non-small cell lung cancer, NSCLC, and other tumor types, with the KRAS G12C present in approximately 9% of NSCLC patients. The mTOR pathway is often activated in patients with the KRAS mutation and contributes to adaptive resistance to KRAS inhibitors. Sotorasib is approved for the treatment of KRAS G12C-mutated locally advanced or metastatic NSCLC, and adagrasib is under review for the treatment of KRAS G12C-mutated NSCLC. This study investigated the antitumor activity of mTOR inhibitors nab-sirolimus or everolimus in combination with sotorasib or adagrasib in KRAS G12C-mutated cancer xenografts. Results of these studies showed that combining nab-sirolimus with either of the KRAS G12C inhibitors significantly improved response against KRAS G12C mutant lung cancer and bladder cancer tumors in vivo and nab-sirolimus also showed significantly greater potency in the combination compared to everolimus. The nab-sirolimus combinations with sotorasib and adagrasib will be detailed in the upcoming poster.

08:06 EDT Synthetic Biologics rebrands as Theriva Biologics - Theriva Biologics is the new name of Synthetic Biologics. The new name, logo and branding elements were introduced to better reflect Theriva's position as a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus platform to address devastating cancers with high unmet need. In addition, the Company announced its common stock is expected to begin trading on NYSE American under the new ticker symbol "TOVX" on Thursday, October 13, 2022. "The rebranding solidifies our strategic transformation and reflects our sharpened focus on advancing unique, oncolytic viruses optimized for IV administration," said Steven Shallcross, CEO of Theriva Biologics. "We continue to build on the incredible progress made to date and are diligently advancing our OV pipeline. This includes lead clinical-stage program VCN-01, designed to break down the tumor stroma, and preclinical-stage program VCN-11, leveraging our proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. These two differentiated programs are intended to improve the anti-tumor effect of the oncolytic virus, co-administered chemotherapies and/or immuno-oncology therapeutics. Together, VCN-01 and VCN-11 position Theriva at the forefronts of oncolytic virus development. We are excited about Theriva's path towards strategic growth, renewed corporate strategy and remain on track to deliver on upcoming value-driving milestones." The rebrand includes a new logo and corporate website that more accurately reflect the Company's vision, mission and values.

08:06 EDT Sprinklr enter partnership with the Abu Dhabi Digital Authority - Sprinklr announced a partnership with the Abu Dhabi Digital Authority to help Abu Dhabi Government Entities, or ADGEs, adopt and scale unified CX programs to improve citizen experiences and engagement across the region.

08:05 EDT FOXO Technologies announces 1st distribution partner, California rollout - FOXO Technologies announced that its insurance distribution subsidiary, FOXO LIFE, recruited its first distribution partner, California-based BGA Insurance, to begin rolling out Life Insurance Designed to Keep You Alive to agents across the state. FOXO also announced the appointment of James Grauel, Jr. as Chief Distribution Officer of FOXO LIFE to spearhead the launch of longevity-focused life insurance products with independent agents. FOXO LIFE is partnering with leading independent insurance agencies across the United States who share its vision and goal of modernizing the industry. Grauel joins the team with decades of experience working in the life insurance industry from both the carrier and independent agent distribution viewpoints. As CDO, Grauel will manage the development of FOXO LIFE's network of independent agents selling longevity science-powered life insurance. "I am thrilled to join a team that is building the most exciting thing I've seen in this industry over the course of my career," said Jim Grauel, Jr., Chief Distribution Officer of FOXO LIFE. "Creating more value for life insurance consumers by aligning their healthy longevity with the natural financial interest of life insurance carriers is an incredible and obvious innovation the industry needs."

08:04 EDT Agenus and VBI Vaccines collaborate in Phase 2 study of glioblastoma candidate - Agenus (AGEN) and VBI Vaccines (VBIV) announced a collaboration to evaluate the combination of VBI-1901, VBI's cancer vaccine immunotherapeutic, and balstilimab, Agenus' monoclonal antibody targeting the programmed death receptor-1 protein, in primary glioblastoma patients as part of the adaptive platform trial, INSIGhT. Under the agreement, VBI will be the study sponsor and will be responsible for operational execution of the combination trial, and Agenus will provide drug supply and scientific support. VBI-1901 is in an ongoing Phase 2a study and has demonstrated encouraging tumor responses and improvement in overall survival compared to historical controls. In the arm that will be advanced into the primary setting, there have been two partial responses and five stable disease observations among 16 patients with recurrent GBM. These tumor responses have translated to clinical benefit with a median overall survival rate of 12.9 months, which compares favorably to the 8-month overall survival historical control in the recurrent setting after treatment with a monotherapy.

08:03 EDT Delta Air Lines, Starbucks launch loyalty program partnership - Delta Air Lines (DAL) and Starbucks (SBUX) announced a strategic partnership that will offer members of Delta SkyMiles and Starbucks Rewards the ability to unlock even more ways to earn rewards at Delta and Starbucks. Starting October 12, U.S. customers who are enrolled in both Delta SkyMiles and Starbucks Rewards loyalty programs can easily link their accounts by visiting either deltastarbucks.com or starbucksdelta.com. Once the accounts are linked, members will earn one mile per $1 spent on eligible purchases at Starbucks, and on days when enrolled members have a scheduled flight with Delta, they will earn double Stars on eligible purchases at participating Starbucks stores. This new benefit is open to currently enrolled members as well as new members of the companies' loyalty programs.

07:58 EDT SunPower, General Motors to power homes with electric vehicles - SunPower (SPWR) and General Motors (GM) announced a collaboration to develop a new home energy system that will enable GM electric vehicles to provide backup energy to a home when properly equipped. GM also named SunPower as a preferred EV charger installation provider and its exclusive solar provider. The collaboration will bring together SunPower's home energy expertise and installation capabilities with GM's leadership in EV and battery technology to help provide customers with more resilient, sustainable and cost-effective energy. The home energy system and installation services are slated to be available alongside the retail launch of the 2024 Chevrolet Silverado EV, expected Fall 2023. With bi-directional charging capabilities, the Silverado EV paired with a home energy system is expected to provide enough electricity to provide whole home backup1 during a grid outage. "We are proud to work alongside GM, a stalwart in American innovation, to seamlessly connect home energy and electric vehicles. This is a vital next step toward making an all-electric lifestyle easy and even more beneficial," said Peter Faricy, SunPower CEO. "Through this collaboration, we are making it easy for EV drivers to power their vehicles with clean energy and providing new ways to offer energy resiliency and peace-of-mind."

07:54 EDT Leap announces first patient enrolled in Part C of Phase 2 DisTinGuish study - Leap Therapeutics announced that the first patient has been enrolled in the randomized controlled Part C of the ongoing DisTinGuish study to evaluate DKN-01, Leap's anti-Dickkopf-1 antibody, in combination with tislelizumab, BeiGene's anti-PD-1 antibody, and chemotherapy compared to a tislelizumab and chemotherapy control arm, in patients with gastric or gastroesophageal junction cancer. "We are excited to announce another important milestone for our DKN-01 clinical program in combination with our partner BeiGene's tislelizumab, advancing this unique combination therapy into Part C of the DisTinGuish study," said Cynthia Sirard M.D., Chief Medical Officer of Leap Therapeutics. "The data to date from the DisTinGuish study show the DKN-01 plus tislelizumab combination therapy to be a compelling potential treatment for patients with G/GEJ cancer with response rates and survival outcomes that exceeded the benchmarks. This first randomized controlled study for DKN-01 will characterize the treatment effect in first-line patients, with a particular emphasis on those in the aggressive DKK1-high population." The DisTinGuish study is a Phase 2 study of DKN-01 in combination with tislelizumab and standard of care chemotherapy in patients with inoperable, locally advanced, G/GEJ adenocarcinoma.

07:50 EDT Bio-Techne announces introduction of new vivid fluorescent dyes - Bio-Techne Corporation announced the introduction of 3 novel TSA Vivid Fluorophores for highly sensitive fluorescent detection of RNAs and proteins in cells and tissues. Optimized for use with proprietary RNAscope ISH technology, the TSA Vivid Fluorophores enable researchers to illuminate RNA biomarkers with industry leading sensitivity and clarity, accelerating cellular phenotyping and functional analysis at single-cell and subcellular resolution. Ideal for use with FFPE and fresh frozen tissue sections, and backed by over 6,600 peer reviewed global publications, RNAscope technology enables robust RNA detection with high specificity for the widest range of diverse RNAs commercially available. When used together with the TSA Vivid Fluorophores, RNAscope enables exceptionally bright detection of gene expression with very low background, including low expressing RNAs, simplifying new assay development.

07:48 EDT KnowBe4 up 12.4% at $24.27 after report of acquisition by Vista Equity

07:37 EDT E-Home Household Service signs multiple household service contracts - E-Home Household Service has signed multiple household cleaning service contracts to provide both daily hygiene maintenance and domestic garbage sorting and dumping services for properties under management of long-term clients in Fujian province, China. Pursuant to the five contracts signed, E-Home will provide cleaning services in public areas including carparks, green belts, passages and public facilities, public restrooms, among others. E-Home would also be providing pests extermination and disinfection services in the public area.

07:34 EDT Fulcrum Therapeutics to present data from OLE portion of Phase 2 ReDUX4 study - Fulcrum Therapeutics announced that new data from the open label extension portion of the Phase 2 ReDUX4 study of losmapimod for the treatment of FSHD will be featured in a poster presentation at the World Muscle Society Hybrid Congress taking place October 11-15 in Halifax, Canada. Fulcrum will also host a symposium entitled "Measuring Progression in FSHD: Implications for Clinical Trials," featuring an overview of the OLE data on October 12, 2022, at the Halifax Convention Center. ReDUX4 was a 48-week, placebo-controlled study that enrolled 80 participants between the ages of 18-65 with genetically confirmed FSHD1. Study participants were randomized 1:1 to receive 15 mg losmapimod twice daily or placebo. Following the initial 48-week study period, all participants were given the option to enroll in the OLE portion of the study during which all participants received losmapimod. Of the 77 participants who completed the initial 48-week study, 99% enrolled in the OLE. At week 96, 74 participants remained on treatment. Data from the OLE support findings that losmapimod modifies FSHD disease progression and preserves or improves muscle function. Patients who crossed over to losmapimod treatment from the placebo arm and remained on treatment through 96 weeks demonstrated trends of slowing or stopping disease progression as measured by reachable workspace. Participants who originally received losmapimod and remained on therapy, continued to show slowing or stopping of disease progression and demonstrated improvement in muscle function, as measured by RWS. Losmapimod maintained a favorable safety profile and was generally safe and well tolerated. No treatment-related serious adverse events or treatment-emergent adverse events leading to study drug discontinuation were reported through 96 weeks of dosing.

07:27 EDT Ionis announces plan for new manufacturing facility in California - Ionis Pharmaceuticals announced that it has entered into an agreement with Sudberry Properties to develop and lease a new development chemistry and manufacturing site in Oceanside, Calif. Sudberry will develop and construct the shell for the approximately 217,000-square-foot building. Ionis will design and construct improvements to customize the facility. Under the terms of the agreement, Ionis will lease the property for 20 years, with two 10-year options to renew and a right of first offer to purchase the property. "From our inception, Ionis has been committed to discovering and developing transformational medicines for patients who depend on us. Our new Oceanside campus will provide the capacity we need to support our growing pipeline, new technologies and chemistries. We're proud to have established and grown our business in North County, San Diego over the last 30 years and delighted that we will continue to grow here for decades to come," said Brett Monia, Ph.D., Ionis' CEO.

07:20 EDT Columbia Bank appoints Manesh Prabhu as EVP, CIO - Columbia Bank welcomes Manesh Prabhu as Executive Vice President, Chief Information Officer, effective immediately. In his role, Mr. Prabhu is responsible for Information Systems and Digital Banking. Prabhu has over 20 years of experience at leading institutions including Peoples United Bank N.A. Most recently, he held the title of Chief Technology Officer where he led the IT strategy and technology transformation for the Bank.

07:17 EDT Farmland Partners acquires two tracts of Illinois farmland for $3.36M - Farmland Partners announced that it acquired two tracts of farmland on Friday, October 7.The corn and soybean farms collectively cover 270 acres in Edgar County, Illinois. The Company spent $1.32M to acquire 82 acres in the first transaction, which will create a contiguous block of farmland spanning more than 1,200 acres when combined with other farms in the portfolio. The Company also purchased a 188-acre parcel for $2.04M. That tract is approximately 7 miles away from the first transaction and is nearby additional FPI properties.

07:16 EDT Evolent Health sees revenue related to Bright Health as flat from 2022 to 2023 - In an 8-K filing yesterday, the company stated: "Evolent Healt (EVH) provided context regarding the announcement by Bright Health Group (BHG), an operating partner of the Evolent Health Services segment of the company, that BHG plans to exit its Individual and Family Plans line of business for 2023. The company had previously announced the selection of Evolent Health Services by BHG as the administrative services provider for this line of business, along with BHG's intention to add approximately 700,000 members beginning January 1, 2023 to approximately 340,000 currently on the EHS platform. The Company had also estimated growth from BHG in the EHS segment would be approximately $70 million for 2023. With the BHG announcement, the company currently anticipates revenue from BHG to be approximately flat in the EHS segment from 2022 to 2023. Since the company's contract with BHG provides for customary runout services and other clauses, the company currently expects minimal impact on EHS segment adjusted EBITDA through the end of 2023 based on this announcement. This announcement also does not change the company's target to meet or exceed mid-teens top-line growth target in 2023 and beyond."

07:11 EDT Colliers International completes acquisition of alternative investment manager - Colliers completed its previously announced acquisition of a controlling interest in Versus Capital, a U.S. alternative real asset management firm with over $6.0B of AUM. The acquisition of Versus raises total Colliers' AUM to $87B.

07:10 EDT ProMIS Neurosciences closes $7.4M private placement - ProMIS Neurosciences announced that it has closed a fully subscribed private placement of 1,383,755 Units of the Company at a price of $5.40 per Unit for gross proceeds of $7,472,277. Each Unit is comprised of one Common Share of the Company and one quarter of one Common Share purchase Warrant. Each full Warrant is exercisable for one Common Share at $7.50 for a period of five years commencing six months from the closing of the Offering.The proceeds from the Offering will be used to advance ProMIS' lead product candidate, PMN310, into a first-in-human study which the Company plans to commence in 2023, subject to FDA's acceptance of an Investigational New Drug Application. Proceeds will also support expansion of the Company's intellectual property portfolio, as well as working capital and general corporate purposes. ProMIS' lead product candidate, PMN310, is a novel monoclonal antibody that is highly selective for toxic oligomers of amyloid-beta which are found in brains of AD patients. ProMIS believes specific targeting of toxic misfolded proteins may directly address fundamental AD pathology while potentially leading to enhanced efficacy and safety compared to other agents due to reduction of off-target activity. ProMIS' pipeline also includes PMN267, an antibody against misfolded TDP-43 for ALS, and PMN442 targeting misfolded toxic forms of alpha-synuclein, a driver of MSA.

07:08 EDT Moving iMage announces approval of Direct View LED frame patent - Moving iMage Technologies announced that the United States Patent Office has granted MiT a patent covering a proprietary design for Direct View LED screen frames in cinemas. The frame was designed by David Richards, MiT co-founder and senior vice president of Engineering, to address specific needs of this new technology as it applies to the cinema theater. The first MiT frame of this type was installed in Richmond, Texas in 2019. Another installation was completed in Buena Park, California this year.

07:07 EDT Royalty Pharma enters schizophrenia R&D funding collaboration with Merck - Royalty Pharma (RPRX) has entered into an agreement with Merck (MRK) to co-fund the development of MK-8189, an investigational oral PDE10A inhibitor currently being evaluated in a Phase 2b study for the treatment of schizophrenia. Royalty Pharma will provide $50M upfront to Merck to support ongoing development of MK-8189. Following Merck's decision to proceed with Phase 3, Royalty Pharma has the option to provide an additional $375M to co-fund the pivotal clinical development program. Royalty Pharma will be eligible for milestone payments associated with certain regulatory approvals for MK-8189 as well as royalties on annual worldwide sales of any approved product.

07:06 EDT Cellebrite releases next generation of Cellebrite Guardian - Cellebrite DI announced the release of the next generation of Cellebrite Guardian, which provides critical features aiding law enforcement in handling digital evidence in an ethical way, including storing, managing, and sharing evidence, with unmatched instant review of digital evidence.

07:05 EDT Atai Life Sciences' KUR-101 shows positive Phase 1 results for opioid abuse - atai Life Sciences announced positive initial results for their Phase 1 clinical trial of KUR-101, an oral formulation of deuterated mitragynine, the major active alkaloid of the kratom plant, under development for the treatment of opioid use disorder, or OUD. Initial results indicate that KUR-101 is safe and generally well-tolerated. Results also showed a dose-proportional pharmacokinetic profile that was unaffected by food. There are currently only three FDA-approved therapeutics for OUD; they produce side effects and about 75% of patients undergoing OUD therapy experience relapse within one year of treatment. KUR-101 is an atypical opioid receptor modulator with unique pharmacology that may make it safer for chronic use. The deuteration of mitragynine improves the PK and overall safety profile of KUR-101 while reducing dosing requirements. Topline results, including Part 2 of the trial comparing a single dose of KUR-101 to a single dose of oxycodone or placebo, are expected by the end of 2022.

07:04 EDT BeiGene announces Brukinsa achieved superior PFS versus Imbruvica - BeiGene announced that Brukinsa achieved superior Progression-Free Survival, or PFS, versus Imbruvica in a final analysis of the Phase 3 ALPINE trial, as assessed by an independent review committee, or IRC, and investigator. Brukinsa was generally well tolerated; safety findings at the final PFS analysis were consistent with prior reports. BeiGene's supplemental new drug application for Brukinsa for the treatment of adult patients with CLL or small lymphocytic lymphoma, or SLL, is currently under review with the FDA, with a target action date of January 20, 2023.

07:02 EDT GreenLight Bioscences announces realignment of focus, staff reduction of 25% - GreenLight Biosciences announced a realignment to focus on key near-term value drivers and extend its cash runway. Key changes include further optimizing GreenLight's organizational structure to better serve the company's operations and more efficiently support the research, development and commercialization of its plant health and human health pipelines, primarily by integrating GreenLight's platform team into the respective teams for human health and plant health. These integrations come with a staff reduction of approximately 25%. In recent months, GreenLight's human health team announced manufacturing mRNA at scale with Samsung Biologics and launched partnerships to develop vaccines with the Vaccine Research Center at the National Institutes of Health and with Serum Institute of India. The plant health team has demonstrated first-of-a-kind field control of fungal pathogens such as Powdery Mildew, with effectiveness on a par with chemical standards. The team has also progressed work to develop RNA seed treatments, partnering with Germains Seed Technology. Field trials of GreenLight's proprietary pollinator solution to protect honeybees showed control of varroa destructor mite similar or superior to a leading chemical alternative after 12 weeks. The company said," For plant health, we continue to work on broadening the pipeline, which includes fungicides and insecticides. There will be particular emphasis on advancing registration and commercialization of the first-ever foliar-applied RNA for crop protection, Calantha, GreenLight's solution for control of the Colorado potato beetle. We will also continue towards regulatory submission of GreenLight's solution targeting varroa mites, which are decimating honeybee colonies around the globe. For human health, our ongoing focus remains on obtaining proof of concept of GreenLight's technology platform with our Covid vaccine and advancing our shingles program in collaboration with Serum Institute of India. Following on the Covid and shingles work, GreenLight plans to continue to work on research programs addressing unmet medical needs in lower and middle income countries. As a result of this realignment, GreenLight will shift its focus from early-stage research programs-including our gene therapy program for sickle cell disease and our programs for antibody therapy and supra-seasonal flu-to opportunities that are nearer to commercialization. We are also reorganizing our operations in order to maximize the efficiency of our team, which we expect will reduce our facilities and other SG&A costs over time. The reductions in headcount are expected to generate savings of approximately $13M in direct employee costs in 2023. In addition, we expect there will be savings from other direct and indirect cost areas.""

06:56 EDT Eagle Pharmaceuticals submits IND application to FDA for CAL02 - Eagle Pharmaceuticals announced that it has submitted an investigational new drug application to the U.S. Food and Drug Administration for CAL02, a novel first-in-class broad-spectrum anti-virulence agent for the treatment of severe community-acquired bacterial pneumonia. The IND filing includes a protocol for an adequately powered global Phase 2 study to evaluate the efficacy and safety of CAL02 when added to standard of care therapy in patients with SCABP. The design, entry criteria, and endpoints for the proposed Phase 2 study have been discussed with the FDA in a pre-IND meeting held on September 19, 2022. The Phase 2 study plans to enroll approximately 276 patients with SCABP at 120 sites worldwide. Patient enrollment is expected as early as the beginning of 2023. Eagle anticipates filing for ten years of regulatory exclusivity, including five years as a new chemical entity and five years as a qualified infectious disease product under the Generating Antibiotic Incentives Now Act. Eagle believes that CAL02 could be eligible for fast track and breakthrough therapy designations. In addition, Eagle believes a CAL02 new drug application for the treatment of SCABP may qualify for priority review. The Company expects to strengthen the patent portfolio for this asset. In August 2021, Eagle entered into a worldwide licensing agreement with Combioxin SA, a clinical-stage biotechnology company based in Epalinges, Switzerland, for the commercial rights to CAL02. As previously announced, the Company expects to invest $35 million to achieve interim results from the Phase 2 study expected in late 2023/early 2024.

06:54 EDT Avangrid, Sempra Infrastructure enter HOA for green hydrogen and ammonia project - Avangrid (AGR), and Sempra Infrastructure, a subsidiary of Sempra (SRE), announced they have entered into a heads of agreement, or HOA, for the potential joint development of U.S. green hydrogen and ammonia projects powered by renewable sources. The HOA provides a framework for the companies to identify, appraise, and potentially develop large-scale green hydrogen projects to help meet the energy and decarbonization needs of both U.S. and international customers. Avangrid's deep background in renewable development as the third largest renewables operators in the U.S., complements Sempra Infrastructure's complex project development and commercial expertise across clean power, energy networks and LNG and net-zero solutions. Sempra Infrastructure is currently developing multiple energy transition projects in North America, including LNG export projects to serve customers in both the Atlantic and Pacific Basins, as well as new opportunities in renewable energy, carbon capture and sequestration, as well as other pathways to produce clean hydrogen and ammonia leveraging the resources available in different regions. The referenced HOA is non-binding, and the development of these joint projects is subject to a number of risks and uncertainties, including reaching definitive agreements, securing all necessary permits, and reaching a final investment decision with respect to each project.

06:50 EDT Owens & Minor appoints Andrew Long, EVP, CEO, Products & Healthcare Services - Owens & Minor announced certain changes to its executive leadership team, including the appointment of Andrew Long as EVP, CEO, Products & Healthcare Services segment, replacing Jeffrey Jochims who will be leaving the Company. Long has served as the Company's EVP and CFO since joining the Company in November 2019. In addition, Alexander Bruni has been promoted to EVP and CFO, replacing Long. Alex Bruni joined Owens & Minor in April 2020 and has served as SVP of Finance, first leading corporate FP&A, then progressing to become the finance leader of the Products & Healthcare Services segment and most recently, the Patient Direct segment.

06:47 EDT Stantec signs LOI to acquire L2P, terms not disclosed - Stantec has signed a Letter of Intent to acquire L2P, a 40-person Philadelphia-based architecture, interior design, and planning firm. Founded in 2009, L2P has grown to be a trusted advisor in the science and technology, commercial workplace, higher education, residential, and hospitality markets. The terms of the transaction are not disclosed. The company said, "The acquisition will bolster Stantec's science and technology and commercial workplace offerings in greater Philadelphia and beyond. L2P brings extensive experience in strategic asset planning that supports clients in reaching informed real estate decisions. L2P's portfolio spans complex laboratories, technology centers, higher education campuses, and high-density residential developments. The team holds a reputation for delivering projects that balance innovative design and sustainability practices with client objectives."

06:41 EDT Wipro sees Q3 IT Services revenue $2.811B-$2.853B

06:36 EDT Armour Residential REIT reports book value per common share $5.79-$5.83 - ARMOUR Residential REIT announced preliminary estimated financial information as of September 30, 2022 and for the three-month period then ended. ARMOUR's Q3 2022 Preliminary Estimates: Book value per common share at September 30, 2022 was between $5.79 and $5.83 compared to $7.25 per common share at June 30, 2022. Securities portfolio included approximately $7.4 billion of agency mortgage-backed securities and U.S. Treasury securities. Debt to equity ratio was approximately 8.8 to 1. Leverage, net of short TBA securities positions, was approximately 7.7 to 1 at September 30, 2022. For comparison, debt to equity ratio was 6.9 to 1 and leverage, including net long TBA securities positions, was 7.6 to 1 at June 30, 2022. Liquidity position consisted of cash and unencumbered Agency MBS of approximately $469 million, as of September 30, 2022. Monthly cash dividends totaled $0.30 per common share for the third quarter. Estimated distributable earnings for the quarter exceeded that amount per share. Our final report of distributable earnings for the third quarter 2022, when available, will include a reconciliation of distributable earnings to the most directly comparable GAAP measure. Per share amounts at September 30, 2022 are based on approximately 132,590,000 common shares issued and outstanding on that date. During the quarter ended September 30, 2022, the Company issued approximately 22,733,043 common shares for average net proceeds of $7.36 per share under its "at the market" offering program and repurchased approximately 780,000 common shares at an average net cost of $4.96 under its stock repurchase program.

06:34 EDT Wallbridge Mining announces assay results from Martiniere Gold Project - Wallbridge Mining Company is pleased to announce that assay results from one of the final holes of its 2022 drill program at the Martiniere Gold Project continue to demonstrate excellent resource growth potential. Martiniere is located 30 kilometres and within trucking distance of the Company's flagship Fenelon gold project and 45 kilometres east of the Detour Lake gold mine on the highly prospective Detour-Fenelon Gold Trend in Northern Abitibi, Quebec. The 2021-2022 drilling program was primarily designed to establish connections between the Martiniere West and Bug Lake Trends and also included several exploration holes, drilling larger-spaced step-outs on the gold-bearing trends and zones. The results announced today come from such an exploration hole, MR-22-036, testing the eastern extent of the gold system. Assay results from the last two exploration drill holes of the 2022 program are pending. Following an initial drill program of 9,380 metres in 2021, the Company has completed 21,400 metres of additional drilling at Martiniere this year. The results from this program, which now includes more than 30,000 metres of drilling by the Company, will provide significant new data for an updated mineral resource estimate at Martiniere scheduled for the first quarter of 2023. Highlights of the 2021 drill program, as reported in the Company's press releases dated October 26, 2021 and February 2, 2022, include 3.68 g/t Au over 22.50 metres in MDE-21-326, 2.21 g/t Au over 36.60 metres in MDE-21-328 and 46.76 g/t Au over 2.40 metres in MDE-21-338. Highlights of the 2022 drill program were reported in the Company's press release dated August 30, 2022 and include 12.27 g/t Au over 5.60 metres in hole MR-22-026, extending the Martiniere West zone along strike by over 400 metres to the southwest; 4.75 g/t Au over 5.50 metres in hole MR-22-020, expanding the Martiniere West zone down-plunge by over 300 metres; and 2.50 g/t Au over 17.35 metres, near-surface in hole MR-22-029 in the area between the Martiniere West and Central zones.

06:29 EDT Calibre Mining reports Q3 gold production 49,081 ounces - Calibre Mining is pleased to announce operating results for the three and nine months ended September 30, 2022. Q3 and Year to Date 2022 Production Overview: Consolidated quarterly gold production of 49,081 ounces, and gold sales of 49,260 ounces; 10% increase in gold production compared to Q3 2021; Nicaragua gold production of 38,928 ounces and Nevada gold production of 10,153 ounces; Nicaraguan Q3 gold pours were negatively impacted due to an unplanned outage at the carbon plant, which is now back up and running; Consolidated YTD gold production of 160,704 ounces, gold sales of 161,530 ounces, on track to deliver full year guidance of 220,000 - 235,000 ounces; Pavon Central Open pit mining permit approved Q2, 2022, on track for production Q1, 2023; Considerable progress made at Eastern Borosi Project including: Recently completed the public consultation process with mining permits expected during Q4, 2022; Advanced early road works and site preparations underway. Q3 2022 Highlights : Continuous expansion of the high-grade gold discovery along strike at Panteon North within the Limon Complex; 52.59 g/t Au over 3.8 m Estimated True Width; 43.09 g/t Au over 3.3 m ETW; 35.18 g/t Au over 2.8 m ETW; 26.02 g/t Au over 8.1 m ETW; Consistent high-grade mineralization demonstrated over a strike length of 400 m coupled with VTEM indicates a positive impact to year-end mineral resource statement. Pan Mine drill results demonstrate strong expansion potential; 3.35 g/t Au over 18.3 m; 0.82 g/t Au over 10.7 m; 0.80 g/t Au over 47.2 m; 1.96 g/t Au over 10.7 m; 0.96 g/t Au over 10.7 m, and Excellent opportunities for growth and, in some cases shallow, higher-grade zones are open for expansion. Darren Hall, President & CEO of Calibre, stated: "Gold poured during the quarter was negatively impacted by the carbon plant outage at Libertad however with increased in progress inventory and higher grades we anticipate a strong Q4 and remain on track to meet our 2022 production guidance of 220,000 - 235,000 ounces. During the quarter we continued to progress development at Pavon Central and Eastern Borosi, preparing to start both satellite sites for production during 2023, setting ourselves up for a grade-driven production increase. We continue to see exciting results from our exploration program across all assets and in particular at Panteon North at the Limon complex with continued high-grade intercepts outside of our 2021 resource estimates. During the quarter we published our 2021 ESG Sustainability Report demonstrating continued progress withing all aspects. Calibre remains committed to delivering positive and sustainable benefits to all stakeholders."

06:24 EDT Liberty Gold appoints Jason Attew as president, CEO - Liberty Gold (LGDTF) announced that Mr. Jason Attew has been appointed President and CEO and Director of the Company, effective October 11, 2022. Mr. Attew succeeds Cal Everett, who will be retiring from his role as President and CEO but will continue as an active and engaged member of the Board of Directors. Attew was most recently President and CEO of Gold Standard Ventures Corp. (GSV) Liberty Gold is also pleased to announce that Mr. Attew will be participating in a private placement as part of his commencement. Mr. Attew will purchase on a private-placement basis 759,494 common shares of the Company at a price of C$0.395 per Common Share, for total gross proceeds of C$300,000. Each Common Share is subject to a statutory 4-month hold from the date of issuance. The private placement is subject to the receipt of all necessary approvals including the approval of the Toronto Stock Exchange and applicable securities regulatory authorities.

06:18 EDT Sinch launches KakaoTalk in Conversation API - Sinch announced it is adding the KakaoTalk channel to its Conversation API which allows enterprise businesses to engage in seamless omnichannel interactions with consumers anywhere in the world. With this latest addition, Sinch is expanding the number of channels enterprises can use to engage with their customers. These include SMS, RCS, WhatsApp, Viber Business, Facebook Messenger, among others - and now KakaoTalk.

06:15 EDT AstraZeneca's Alexion to present new data on advancement in treating NMOSD - The company states: "Alexion, AstraZeneca Rare Disease, will present new data showing significant advances for the treatment of anti-aquaporin-4, AQP4, antibody-positive neuromyelitis optica spectrum disorder, NMOSD, at the European Committee for Treatment and Research in Multiple Sclerosis Congress, 26 to 28 October 2022. Data presented at the meeting will feature new insights from Alexion's complement portfolio illustrating the critical role of C5 inhibition in treating AQP4 Ab+ NMOSD and significantly reducing the risk of relapses, including findings on the first and only long-acting C5 complement inhibitor, Ultomiris." Reference Link

06:12 EDT Torex Gold Resources reports Q3 gold production of 122,200 ounces - Torex Gold Resources reports Q3 2022 gold production of 122,200 ounces for the quarter ended September 30, 2022 from its El Limon Guajes mining complex in Mexico. With 357,830 ounces produced through the end of the third quarter, the Company is tracking towards the upper end of 2022 production guidance of 430,000 to 470,000 ounces. During the quarter, Torex sold 119,830 ounces of gold, resulting in year-to-date gold sales of 351,200 ounces. Jody Kuzenko, President & CEO of Torex, stated: "We delivered another quarter of solid operational results with gold production of 122,200 ounces, driven largely by excellent mill performance with throughput averaging more than 13,000 tonnes per day , record-setting gold recoveries of close to 90%, and sustained elevated underground mining rates at 1,550 tpd. With 357,830 ounces of gold produced year to date, we are well on track to deliver towards the upper end of 2022 production guidance, high end of total cash cost guidance and mid-point of all-in sustaining cost guidance. At ELG Underground, we completed the Portal #3 ramp to the existing reserve at depth and started exploration drilling. In addition, raise boring began with a view to completing ore pass construction in Q1 2023 to connect the upper levels to this new area - both of which are key to further optimizing and extending ELG Underground. In the open pit, waste stripping was prioritized in the quarter. Development activities at Media Luna continue to ramp-up with the procurement phase well underway and long lead earthworks progressing to plan. During the quarter, purchase orders were executed for the Guajes conveyor, regrind mills, and flotation cells. At the end of September, the Guajes Tunnel advanced 2,660 metres and South Portal Lower advanced 1,055 metres. Breakthrough of the Guajes Tunnel on the south side of the Balsas River remains on track with the Feasibility Study schedule of Q1 2024. Overall, we are well positioned to close out 2022 exactly as we planned, delivering on full year guidance for the fourth year in a row and carrying strong momentum on operations and project execution into 2023."

06:08 EDT Global Net Lease provides update on leases in Q3 - Global Net Lease announced that in the third quarter it executed one new lease, one expanded lease, and two lease extensions. These leases, which are for properties located in the U.S. and UK, have a new weighted-average remaining lease term of 9.1 years, an increase of almost four years compared to the old lease term. Year-to-date, GNL has signed new, renewed or expansion leases totaling 3.6M square feet with a weighted-average remaining lease term of 9.4 years which increases the amount of straight-line rent these tenants are required to pay by approximately $1M based, in part, on existing exchange rates for the leases with tenants in the UK and Europe. The leases signed in 2022 are for properties the company owns in the U.S., UK, France and the Netherlands and include investment-grade tenants such as the US Government, the State of Indiana, FedEx, and Whirlpool.

06:06 EDT Lizhi receives minimum bid price notification from Nasdaq - Lizhi has received a written notification from Nasdaq's Listing Qualifications Department indicating that for the last 30 consecutive business days, the closing bid price of the company's ADSs was below the minimum bid price of $1.00 per share. The Nasdaq notification letter has no current effect on the listing or trading of the company's ADSs on Nasdaq. The company is provided with a compliance period of 180 calendar days, or until April 10, 2023, to regain compliance. The company may be eligible for an additional 180-day compliance period if it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards, with the exception of the bid price requirement, and provides written notice of its intention to cure the deficiency. The Nasdaq notification letter does not affect the company's business operations.

06:04 EDT Cachematrix by BlackRock launches mobile app for liquidity investors - Cachematrix announced clients of the Cachematrix by BlackRock portal will now be able to access the liquidity marketplace via a mobile application. Leveraging Cachematrix's decades of experience integrating with treasury management, bank and custody systems, Cachematrix by BlackRock will now offer its users a multichannel experience, providing real time monitoring of clients' accounts with the convenience of mobile access.

06:03 EDT Carvana rolls out co-signer financing in Yonkers - Carvana makes its vehicle financing qualification process even easier by offering Yonkers residents the ability to add a co-signer to buy the vehicle they love. By sharing responsibility for the vehicle loan, Carvana customers in Yonkers who qualify may unlock more attractive financing offers, including lower down payments, lower interest rates, or lower monthly payments.

06:02 EDT Carvana rolls out co-signer financing in Buffalo - Carvana makes its vehicle financing qualification process even easier by offering Buffalo residents the ability to add a co-signer to buy the vehicle they love. By sharing responsibility for the vehicle loan, Carvana customers in Buffalo who qualify may unlock more attractive financing offers, including lower down payments, lower interest rates, or lower monthly payments.

05:49 EDT Uxin announces one-for-ten ADS ratio change - Uxin announced that it plans to change the ratio of its American Depositary Shares, or ADSs, to Class A ordinary shares from one ADS representing three Class A ordinary shares to one ADS representing 30 Class A ordinary shares. This ratio change will have the same effect as a one-for-ten reverse ADS split for Uxin's ADSs holders. There will be no change to Uxin's underlying Class A ordinary shares, and no Class A ordinary shares will be issued or cancelled in connection with this ratio change. No action is required by holders of ADSs to effect the ratio change, as the change will be effected on the books of the ADS depositary. Following the ratio change, Uxin's ADSs will continue to be traded on Nasdaq.

05:45 EDT Evofem announces EVOGUARD trial did not achieve endpoints - Evofem announced that the recently completed Phase 3 EVOGUARD clinical trial evaluating EVO100 for the prevention of chlamydia and gonorrhea infection in women did not achieve its endpoints. The product safety profile was consistent with what has been observed in prior clinical trials, and only two women in the study discontinued due to adverse events. As previously reported, Evofem has experienced strong growth in net sales of Phexxi, as well as market access expansion, as payers and pharmacy benefit managers, or PBMs, continue to add Phexxi to their formularies, allowing women to fill their prescriptions immediately. At this time, the company will focus on continuing to meet the unmet contraceptive need of millions of women with Phexxi but will discontinue further investment in the development of this STI clinical program due to financial resources.

05:33 EDT Philips sees Q3 group revenue EUR 4.3B - Philips provided an update on its third-quarter financial results and full-year outlook. The company will report the final results on October 24. Philips' financial performance in the third quarter was largely impacted by continued supply chain challenges that were more significant than anticipated in the quarter, impacting deliveries and customer installations. As a result, sales for the group are expected to be approximately EUR 4.3B with a comparable sales decline of approximately 5%. Philips' Diagnosis & Treatment businesses are expected to show a low-single-digit comparable sales decline and the Connected Care businesses a mid-teen decline, while the Personal Health businesses are expected to show mid-single-digit comparable sales growth. As a consequence of the lower sales, group adjusted EBITA for the quarter is expected to be approximately EUR 210M or approximately 5% of sales. On the back of 47% comparable order intake growth in the third quarter of last year, Philips' comparable order intake in the third quarter of 2022 declined approximately 6%. The book-to-bill ratio remained strong at 1.18 and the equipment order book grew further in the quarter. Philips expects to record a EUR 1.3B non-cash charge in the third quarter for the impairment of goodwill of its Sleep & Respiratory Care business due to revisions to the financial forecast of this business. The drivers for the revised forecast include current assumptions regarding the estimated impact of the proposed consent decree and changes to the pre-tax discount rate. Philips is accelerating productivity initiatives and other actions to mitigate the ongoing headwinds, that will be further detailed on October 24. As a consequence of the earlier announced initiative to enhance productivity in R&D by shifting the focus to fewer and better resourced projects in the innovation pipeline, Philips expects to record a non-cash charge in the third quarter of approximately EUR 165M. Looking ahead, Philips still expects a better second half of the year, compared to the first half of 2022. However, the company sees prolonged supply chain disruptions and a worsening macro-environment. Consequently, Philips now expects a mid-single-digit comparable sales decline for the fourth quarter with a high-single-to-double-digit adjusted EBITA margin range.

05:20 EDT Elbit Systems awarded $107M ENVG-B Army order - Elbit Systems announced that its U.S. subsidiary, Elbit Systems of America, was awarded an order valued at approximately $107M for the supply of Enhanced Night Vision Goggle - Binocular, or ENVG-B, systems, spare parts, logistics support, and test equipment, for the U.S. Army. The order will be executed in Roanoke, Virginia and will be supplied during the years 2023 and 2024. This order is part of an Other Transaction Authority, or OTA, contract that Elbit Systems of America received in 2020, with a potential value that could reach a maximum of $442M. The ENVG-B integrates powerful night vision capabilities and head-up situational awareness. ENVG-Bs are equipped with high performance white phosphor image intensifier tubes for better scene contrast providing soldiers better situational awareness in the dark, but also when there is fog, dust, or smoke. The ENVG-B system includes a wireless connection to soldiers' rifle-mounted thermal weapon site and augmented reality overlay, enabling rapid target acquisition and improved situational awareness in various battlefield conditions.

05:10 EDT Microsoft, Mercedes-Benz collaborate to enhance vehicle production - Mercedes-Benz and Microsoft will collaborate to make vehicle production more efficient, resilient and sustainable. With the new MO360 Data Platform, Mercedes-Benz is connecting its around 30 passenger car plants worldwide to the Microsoft Cloud. The MO360 Data Platform is the evolution of Mercedes-Benz' digital production ecosystem MO360 and allows teams to identify potential supply chain bottlenecks faster and enable a prioritization of production resources toward electric and top-end vehicles. This unified data platform is standardized on Microsoft Azure, providing Mercedes-Benz with flexibility and cloud computing power to run AI and analytics at global scale while addressing cybersecurity and compliance standards across regions. The platform is already available to teams in EMEA and will be deployed in the United States and China.